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Abstract
Excessive midbrain iron accumulation in Parkinson’s Disease (PD) contributes to degeneration of
the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA). Despite this understanding,
there are no validated PD biomarkers. Magnetic resonance imaging (MRI) can localize and quantify brain
iron for diagnosis of PD. Seventeen early-stage PD patients and twenty-one controls were scanned with 3Tesla and 7-Tesla MRI. Using quantitative susceptibility mapping (QSM) and R2* relaxometry, we
analyzed the average iron content in the SNc, substantia nigra pars reticulata (SNr), and VTA. QSM
detected significantly higher SNc iron content in PD patients compared to controls at both field strengths.
R2* only detected differences at 7-Tesla and showed lower sensitivity and diagnostic accuracy in diagnostic
biomarker analyses. As predicted, the SNr and VTA were spared from iron accumulation. SNc iron
overload in early-stage PD, best detected using QSM, could be the first diagnostic biomarker of PD
following validation.
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Summary for Lay Audience
Parkinson’s disease (PD) is a neurodegenerative disorder that impacts movement and
thinking. Loss of cells in a brain area called the substantia nigra contributes to PD. When
neurologists diagnose PD based on clinical symptoms, up to 80% of these cells have already
degenerated. Therapy becomes less effective with progressing degeneration, which means early
diagnosis is vital for more effective treatment and improved patient outcome.
Excessive iron buildup in the substantia nigra cells in PD could potentially identify the
degeneration based on previous research findings. This highlights an importance to precisely locate
and measure brain iron for potential uses in early diagnosis. Magnetic resonance imaging (MRI)
can image brain iron and look for excessive iron buildup. This study aimed to use iron imaging
based on MRI methods to determine if this technique can improve diagnosis of PD.
Our study used two different iron imaging techniques in two MRI scanners to measure
brain iron in early-stage PD patients and healthy elderly adults. Excessive iron buildup was
detected only in a subregion called the substantia nigra pars compacta (SNc), which is the first
area affected by PD. The other two areas had no changes in brain iron because they are affected in
later stages of PD. Consequently, iron imaging is most effective when using SNc iron levels for
early diagnosis of PD. The newer iron imaging technique had better diagnostic accuracy when
using SNc iron to sort PD patients from healthy adults. Our research suggests newer iron imaging
techniques could diagnose PD though more work is needed to determine its accuracy and reliability
in clinical settings. This research could have a major impact on our understanding of PD, the way
it is diagnosed, and ultimately the improvement of patients’ lives.
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Chapter 1: Introduction
1.1.1 Parkinson’s Disease Pathology in the Midbrain
Dr. James Parkinson first described Parkinson’s disease (PD) in his work titled, ‘An Essay
on the Shaking Palsy’ (Parkinson, 1817). While he described the motor symptoms of PD, he stated
that the senses and intellects are uninjured in the disease (Parkinson, 1817). Since then, research
has shown that PD does in fact present with non-motor symptoms such as anxiety, depression, and
difficulty with concentration (Barone et al., 2009; Pfeiffer, 2016). These non-motor symptoms
occur in almost all PD patients (98.6%) with about eight symptoms per patient based on a largescale multi-centre study (Barone et al., 2009). To better understand the symptomology of PD, we
must assess the underlying pathology that causes this progressive, neurodegenerative disorder.
The substantia nigra (SN) is composed of two distinct subregions: the substantia nigra pars
compacta (SNc) and the substantia nigra pars reticulata (SNr; Gibb & Lees, 1991). The cardinal
feature of PD is the loss of midbrain dopaminergic neurons in the SNc (Hornykiewicz, 1998).
Degeneration of the SNc neurons produces the core motor symptoms of PD: resting tremor,
rigidity, postural instability, and bradykinesia or slowness of movement (Fahn & Sulzer, 2004;
Jankovic, 2008). Using histological assessment of PD brains, Gibb and Lees (1991) found the
ventral tier of the SNc had few surviving neurons with cell preservation in the dorsal tier. In
humans, the ventral SNc neurons project to the putamen and dorsal caudate regions of the striatum
(Smith & Parent, 1986). Thus, loss of ventral SNc neurons results in greater dopamine depletions
in these striatum regions, creating an uneven pattern of dopamine depletion in PD (Gibb & Lees,
1991; Kish, Shannak, & Hornykiewicz, 1988).
At disease onset, PD will impact one side of the body more than the other, thus presenting
in an asymmetric fashion (Verreyt, Nys, Santens, & Vingerhoets, 2011). A demographic study of
over 300 PD patients found that about 85% showed asymmetric symptom presentation (Yust-Katz,
Tesler, Treves, Melamed, & Djaldetti, 2008). This asymmetry remains throughout the disease
course and is associated with uneven dopaminergic degeneration in the ventral SNc (Verreyt et al.,
2011). Asymmetry is an important clinical feature in early-stage PD and further highlights the
uneven dopamine depletion (Jankovic, 2008). This pattern of selective neuron degeneration is
unrelated to ageing processes, which preferentially affect the dorsal SNc (Scherman et al., 1989).
In addition, post-mortem ageing studies found an SNc neuronal loss of 5-6% per decade, which
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cannot account for the degeneration of 60-80% of neurons at the time of PD diagnosis (Fearnley
& Lees, 1991; Scherman et al., 1989). It is evident that degeneration in the SNc is central to PD
pathology, with vulnerability differences in dorsal and ventral tiers, as well as brain hemispheres.
Early research into the ventral tegmental area (VTA) assumed this dopaminergic midbrain
nucleus was spared in PD due to: the different neuronal population (Nair-Roberts et al., 2008),
differences in calcium channel expression (Mosharov et al., 2009), lower expression of dopamine
transporters (Lammel et al., 2008), and the different levels of α-synuclein (Pan & Ryan, 2012). A
literature review later revealed the VTA unequivocally degenerates in PD and its dopaminergic
neuronal loss can explain the non-motor symptoms of PD (Alberico, Cassell, & Narayanan, 2015).
For example, loss of VTA projections to the ventral striatum and prefrontal cortex could explain
why 25% of PD patients experience anxiety or depression (Aarsland et al., 2010) and nearly 30%
have executive dysfunction (Elgh et al., 2009). Though this is made with caution as dopaminergic
systems are not the only ones affected in PD progression (Narayanan, Rodnitzky, & Uc, 2013).
Recognition of the vulnerability of the VTA helped researchers appreciate why the area is
affected later on and to a lesser extent than the SNc (Alberico et al., 2015). Reyes and colleagues
(2012) found higher co-expression of calbindin and tyrosine hydroxylase, the dopamine producing
enzyme, in the VTA. This co-expression results in lower dopamine release, which may result in
less oxidative stress and neurotoxicity (Alberico et al., 2015). In a recent study, Hare and
colleagues (2014) assessed an iron-dopamine co-expression index as a marker of PD susceptibility
to oxidative stress. In their mouse model of PD, the SNc had a significantly higher iron-dopamine
index than the VTA when accounting for differences in nucleus size, which suggests a higher
susceptibility to oxidative stress in the SNc (Hare et al., 2014). The properties of iron, its
abundance in the midbrain, and its involvement in generation of oxidative stress make iron a useful
tool for understanding these nuclei and their role in PD pathophysiology.

1.1.2 The Role of Iron in Parkinson’s Disease Pathology
Research has provided evidence supporting an oxidative stress hypothesis playing a major
role in PD pathology (Chinta & Andersen, 2008). The brain is most susceptible to oxidative stress
because of the presence of high amounts of polyunsaturated fatty acids, low levels of antioxidants
such as glutathione, and elevated iron content (Chinta & Andersen, 2008; Sies & Cadenas, 1985).
Oxidative damage in PD includes increased lipid peroxidation products, protein oxidation
2

including cross-linking, fragmentation and carbonyl group formation, as well as DNA oxidation
products (Jenner, 2003). It is not clear, however, if oxidative stress in PD is a primary event or
consequent to other cellular dysfunctions (Chinta & Andersen, 2008).
Oxidative stress is essential for the generation of PD symptomology in established animal
models of the disorder (Chinta & Andersen, 2008). For example, 6-hydroxydopamine (6-OHDA),
a common neurotoxin is known to destroy dopaminergic neurons through free radical-mediated
mechanisms (Blum et al., 2001; Hare et al., 2014). Similarly, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) inhibits mitochondrial complex I which enhances superoxide formation that
initiates neuronal death (Blum et al., 2001; Pennathur, Jackson-Lewis, Przedborski, & Heinecke,
1999). These observations lend support to oxidative stress being a primary event as two wellestablished PD animal models require the presence of oxidants for symptom generation.
Furthermore, antioxidants such as glutathione are drastically depleted in the SNc of PD
patients (Bharath, Hsu, Kaur, Rajagolapan, & Andersen, 2002; Sofic, Lange, Jellinger, & Riederer,
1992). Glutathione depletion parallels PD severity and is the earliest known indicator of SNc
degeneration, reportedly preceding changes in striatal dopamine and mitochondrial complex I
(Jenner, 1993; Jenner & Olanow, 1996). Decreased glutathione promotes mitochondrial damage,
protein oxidation, protein aggregation, and reduced mitochondrial complex I activity (Albers &
Beal, 2000; Haas et al., 1995). The depleted glutathione is specific to the SNc of PD patients, with
no major alterations to other dopaminergic neurons (Bharath et al., 2002). Research suggests this
depletion is caused by increased removal of SNc glutathione because synthesis of glutathione and
its oxidation are intact in early-stage PD (Sian et al., 1994). These observations suggest an early
redox imbalance exists in PD with reduced antioxidants, which promote oxidative stress.
Therefore, oxidative stress could exist as both an initiator of neurodegeneration and a component
of the pathogenetic process accelerating neuronal loss (Berg, Youdim, & Reiderer, 2004).
As an abundant oxidant in the SNc, iron also plays a role in the redox imbalance, which
could explain PD pathology. The first investigations of brain iron were conducted by Spatz (1922)
who found the SN and globus pallidus gave the strongest iron reaction when using histology
(Friedman & Galazka-Friedman, 2012). Regions of the brain associated with motor behaviour tend
to have higher iron than non-motor areas (Crichton & Ward, 2014). Hallgren and Sourander (1958)
followed up this work by assessing the effects of age on iron in the brain. Rapid increases occur in
the first two decades, followed by a slower increase in these ‘high iron’ structures throughout the
3

lifespan (Hallgren & Sourander, 1958). The majority of brain iron is stored in the protein ferritin
that forms a large protein cage in which thousands of Fe(3+) atoms are sequestered in mineral
ferrihydrite form (Honarmand Ebrahimi, Hagedoorn, & Hagen, 2015). Looking at post-mortem
iron and ferritin levels, Dexter and colleagues (1991) found elevated iron and reduced ferritin in
the SNc of PD patients. The authors proposed that the release of iron from ferritin causes oxidative
stress and cell death through free radical generation (Dexter et al., 1991).
Another iron-binding molecule linked with PD vulnerability is the pigment neuromelanin
(Zucca et al., 2017). Neuromelanin is the major iron storage molecule in dopaminergic neurons of
human SNc where it also acts as an ‘iron sink’ and a potential source of toxic iron if its capacity
becomes saturated (Hirsch, Graybiel, & Agid, 1988; Zecca et al., 2001a; Zecca et al., 2001b;
Zecca, Youdim, Riederer, Conner, & Crichton, 2004; Zucca et al., 2014). Neuromelanin has a
ferritin-like center that binds iron with high affinity, where iron is stabilized (Aime et al., 1997;
Shima et al., 1997), and another site which binds iron with lower affinity (Zucca et al., 2017). It
may be that once high affinity sites of neuromelanin are saturated, the excess iron in PD may bind
lower affinity sites from where it can be released as ‘free’ iron (Zucca et al., 2017).
Interestingly, glutathione is the natural ligand for ‘free’ iron found in the labile iron pool
(Guiney, Adlard, Bush, Finkelstein, & Ayton, 2017). This labile iron pool is defined as a pool of
chelatable and redox-active iron in complexes of low stability that is between uptake and longterm storage (Guiney et al., 2017; Zucca et al., 2017). The depletion of glutathione in PD leads to
an increase in free iron within the labile iron pool, which could have neurotoxic effects (Kaur, Lee,
Ragapolan, & Andersen, 2009). With ageing and degenerative processes such as PD, there is an
abnormal, progressive deposition of iron and increased free iron concentration in the SNc of PD
patients (Sian-Hulsman, Mandel, Youdim, & Riederer, 2011).
In PD, there is also a change in the type of free iron that is found in cells. The ratio of
Fe(2+) to Fe(3+) increases from 1:2 to almost 2:1, which allows Fe(2+) to form hydroxyl radicals
via the Fenton and Haber-Weiss reactions, ultimately causing oxidative stress (Dexter et al. 1991;
Riederer et al. 1989; Sofic et al. 1988). In the presence of reduced metals such as Fe(2+), hydrogen
peroxide can be converted into hydroxyl radicals by the Fenton reaction and Haber-Weiss reaction
(Youdim & Riederer, 1993). The hydroxyl radical is highly reactive and extremely toxic, making
it the most harmful of all reactive oxygen species in oxidative stress (Crichton & Ward, 2014;
Dlouhy & Outten, 2013; Sian-Hulsmann et al., 2011). Unsaturated fatty acids in cell membranes
4

donate electrons to hydroxyl radicals causing destruction of membranal lipids through the
accumulation of lipid peroxides (Sian-Hulsmann et al., 2011). Iron accumulation can also facilitate
neurotoxic processes through mechanisms apart from this Fenton chemistry (Zucca et al. 2017).
It was thought that the majority of regulated cell death in neurons resulted from caspasedependent apoptosis, which could explain the underlying cause of PD (Fuchs & Steller, 2011;
Thompson, 1995). In fact, neurodegenerative mechanisms originating from iron toxicity can
eventually lead to classical apoptosis (Ott, Gogyadze, Orrenius, & Zhivotovsky, 2007). Recently,
our understanding of PD pathology has incorporated non-apoptotic mechanisms and a unique irondependent form of cell death was termed ferroptosis by Dixon and colleagues (2012). Ferroptosis
is initiated by the failure of glutathione-dependent antioxidant defense mechanisms and an
excessive iron build-up resulting in lipid peroxide accumulation and eventual cell death (Cao &
Dixon, 2016; Dixon & Stockwell, 2014). Notably, the key difference between ferroptosis and
apoptosis is the release of intracellular fluid and lipid metabolites as neurons degrade through
ferroptosis pathways (Hambright, Fonesca, Chen, Na, & Ran, 2017). This release leads to
inflammation, which is another prominent feature of PD and other neurodegenerative diseases
(Tufekci, Meuwissen, Genc, & Genc, 2012). It is evident that depleted glutathione, excess iron
accumulation, and pro-oxidant redox imbalances causing oxidative stress could all worsen SNc
degeneration through ferroptosis and other cell death pathways in PD.
The hypothesis of ‘iron-facilitated’ neurodegeneration is supported by in vitro studies
showing aggregation of α-synuclein and hyper-phosphorylated tau, both of which are involved in
neurodegeneration, can be triggered by iron accumulation (Hashimoto et al., 1999; Li, Jiang, Song,
& Xie, 2010; Yamamoto et al., 2002). Furthermore, iron can directly promote the aggregation of
amyloid-β (House et al., 2004; Schubert & Chevion, 1995) and modulate amyloid precursor
protein pathways (Exley, House, Polwart, & Esiri, 2012; Silvestri & Camaschella, 2008). While
ferroptosis clearly has explanatory potential for neuronal changes in PD, a concern remains
regarding its ability to explain the cell type-specificity of the disorder (Zucca et al., 2017). In other
words, can excess iron accumulation explain midbrain dopaminergic neuronal degeneration in PD.
First, iron is essential in the synthesis of catecholamine neurotransmitters like dopamine,
epinephrine, and serotonin because these molecules are produced by iron-dependent enzymes
(Beard, 2003; Flydal & Martinez, 2013; Windahl, Petersen, Christensen, & Harris, 2008). Iron
also affects other steps of catecholamine metabolism, such as uptake, synaptic concentration,
5

receptor interaction, and catabolism (Beard, Chen, Connor, & Jones, 1994; Bianco et al., 2008;
Burhans et al., 2005; Youdim, Ben-Shachar, & Yehuda, 1989; Zucca et al., 2017). Given these
observations, there is already an apparent connection between iron and dopamine.
Importantly, dopamine can be oxidized to form highly toxic quinones and the rate of
quinone formation greatly increases in the presence of excess iron (Figure 1; Billings et al., 2019;
Paris et al., 2005; Sulzer & Zecca, 2000). Aminochrome is a quinone that under normal conditions
is necessary for the formation of neuromelanin, which has neuroprotective effects and accumulates
with age in SN dopaminergic neuron cell bodies (Figure 1; Bisaglia, Mammi, & Bubacco, 2007;
Zecca et al., 2002). However, dopamine quinones can also participate in neurotoxic reactions.
Dopamine-o-quinone is likely the most reactive o-quinone species responsible for the oxidative
stress induced by DA oxidation (Bisaglia, Soriano, Arduini, Mammi, & Bubacco, 2010). The
depletion of glutathione in dopaminergic neurons would be the consequence of the rapid
nucleophilic addition of glutathione to dopamine-o-quinone (Tse, McCreery, & Adams, 1976).
Aminochrome interacts with human α-synuclein, inducing and stabilizing the formation of
neurotoxic oligomers (Figure 1; Munoz et al., 2015; Norris et al., 2005). The neurotoxicity of
α-synuclein oligomers depends on the silencing of DT-diaphorase enzyme, which reduces
aminochrome to leukoaminochrome (Munoz et al., 2015). Aminochrome also induces protein
degradation dysfunction by impairing proteasomes in vitro (Figure 1; Xiong, Siegel, & Ross, 2014;
Zafar, Siegel, & Ross, 2006), inhibiting autophagy (Paris et al., 2010), and inducing lysosomal
dysfunction (Huenchuguala et al., 2014). In addition, aminochrome forms adducts with
mitochondrial complex I in dopaminergic cells, inducing mitochondria dysfunction and inhibiting
ATP production (Figure 1; Aguirre et al., 2012). Lastly, aminochrome can induce oxidative stress
through superoxide formation in a redox cycling between aminochrome and leukoaminochromeo-semiquinone radical (Figure 1; Arriagada et al., 2004).
Clearly, there is substantial evidence to suggest that oxidative stress derived from the
combined presence of low glutathione, excessive free iron, and dopamine contribute to
dopaminergic neuronal loss in PD and the pathology of this disorder. Regardless of the status of
iron accumulation as either a primary or secondary neurodegenerative event, the overload is a
potential marker of the parkinsonian disease state (Ayton & Lei, 2014).
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Dopamine

Iron-dopamine complex

Neuroprotective Effects

N
Neuromelanin

Neurotoxic Effects
Figure 1. Neurotoxicity of iron-dopamine interactions underlying PD pathology in dopaminergic
neurons. Dopamine forms a complex with Fe(3+) that is taken up into the cell where iron oxidizes dopamine
to aminochrome. Then aminochrome can polymerize to neuromelanin via 5,6-indolequinone affording
neuroprotection. Aminochrome-induced neurotoxic reactions include: α-synuclein oligomerization, protein
degradation dysfunction, mitochondria dysfunction, and oxidative stress caused by redox cycling between
aminochrome and leukoaminochrome-o-semiquinone radical. This redox cycling forms superoxide then
hydrogen peroxide, which in the presence of ferrous iron forms hydroxyl radical leading to high oxidative stress.
(Adapted from Zucca et al., 2017).
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1.1.3 The Need for Biomarkers of Parkinson’s Disease
Biomarkers are a broad subcategory of medical signs, which reflect a characteristic of
biological processes and can be measured accurately and reproducibly (Strimbu & Tavel, 2011).
Currently, there are no validated biomarkers of PD, but many groups have searched for reliable
and objective biomarkers of the disease (Du, Lewis, Sica, Kong, & Huang, 2019; Khan et al., 2019;
Pyatigorskaya et al., 2018; Saeed et al., 2017). Several magnetic resonance imaging (MRI)
biomarkers have been used to detect SNc neurodegeneration (Pyatigorskaya et al., 2018). MRI
techniques such as diffusion tensor imaging, neuromelanin imaging, R2* relaxometry and
susceptibility mapping have shown ability to distinguish PD patients from healthy controls
(Pyatigorskaya et al., 2018). Although several candidates have been discovered, important
challenges remain in translation to clinical practice and clinical trials research (Du et al., 2019).
Biomarkers of PD can be classified into diagnostic, progression, and preclinical categories
(He et al., 2018; Khan et al., 2019). Diagnostic biomarkers can distinguish PD patients from
controls and ideally other Parkinsonian disorders, as they enter the clinical phase of the disease.
Progression biomarkers change over the course of the disease allowing us to distinguish between
early-stage and late-stage PD, as well as provide objective endpoints for assessing the potential of
treatments to modify disease course (Khan et al., 2019). Lastly, preclinical biomarkers index
biological changes in patients who are in the preclinical and prodromal stages before the onset of
motor symptoms when they are actually diagnosed with PD. Preclinical biomarkers would allow
us to predict the development of PD in a healthy population and to potentially intervene at earlier
stages when therapy could be most effective (He et al., 2018; Postuma & Berg, 2016).
The development of reliable biomarkers is critical to aid diagnosis, improve clinical trials,
and measure the efficacy of novel disease-modifying treatments (Miller & O’Callaghan, 2015;
Tuite, 2016). Without diagnostic biomarkers, patients require time-consuming clinical assessment
by clinicians with specialized training to diagnose PD. Furthermore, individuals without PD are
inadvertently enrolled in clinical trials, which compromises their findings. Without progression
biomarkers that can track disease advancement, the efficacy of disease-modifying treatments
cannot be ascertained. Clinical response is highly subjective and variable due to fluctuating
symptoms, making it an unreliable endpoint in clinical trials. In addition, clinical response
confounds symptom alleviation with actual disease-modifying effects of a treatment that is under
investigation (Strimbu & Tavel, 2010). Lastly, without preclinical biomarkers, diagnosis occurs
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too late in the disease course for potential neuroprotective or therapeutic treatment as the majority
of SNc neurons are compromised (Postuma & Berg, 2016). Preclinical biomarkers would improve
clinical trials by inclusion of patients who are most likely to develop PD (Postuma, 2017). It is
clear that biomarkers are important for diagnosis, prognosis, and prediction of PD. Biomarkers are
needed to improve clinical practice along with clinical trials in PD. The discovery of PD
biomarkers can lead to enhanced diagnosis, accurate tracking of disease advancement, and most
importantly the improvement in patients’ quality of life.

1.2.1 Iron Imaging using Magnetic Resonance Imaging
MRI allows for non-invasive, in vivo imaging of brain iron based on the interaction of
atoms with the magnetic field (Ward, Zucca, Duyn, Crichton, & Zecca, 2014). MRI is the most
powerful and sensitive imaging technique for detecting iron (Dusek, Dezortova, & Wuerfel, 2013).
The interaction is based on susceptibility, a measure of the extent to which a substance becomes
magnetized when placed in an external magnetic field (Duyn, 2013). Normally, susceptibility is
responsible for the artefacts in MRI; however, this property can serve as the signal rather than
noise and provide valuable information (Acosta-Cabronero et al., 2018; Li & Leigh, 2004).
When a substance interacts with a magnetic field, an internal magnetization or polarization
is created that either opposes or augments the external field. If the polarization opposes the field,
the substance is diamagnetic as is observed with water, fat and calcium (Haacke et al., 2015). If
the polarization is in the same direction as the external field, then depending on the degree of this
augmentation the substance is said to be paramagnetic (eg. iron salts), superparamagnetic
(eg. ferritin), or ferromagnetic (eg. pure iron; Ghassaban, Liu, Jiang, & Haacke, 2019). Most
biological tissues are weakly diamagnetic, but tissues with focal accumulation of iron are
paramagnetic, such as the midbrain nuclei (Ropele & Langkammer, 2017).
Using conventional magnitude imaging, the findings of most neurodegenerative diseases
are negative (Zhang et al., 2010). Typically, a gradient echo (GRE) sequence is used given that
these sequences are more affected by susceptibility (Elster, 1993). A GRE is produced by a single
radiofrequency pulse in conjunction with a gradient reversal, which refocuses only the spins that
have been dephased by action of the initial radiofrequency pulse itself (Winkler, 1988). Thus,
phase shifts resulting from static tissue susceptibility are not cancelled meaning these sequences
are influenced by susceptibility, which allows for iron imaging (Sethi et al., 2019).
9

1.2.2 Relaxometry and Susceptibility Weighted Imaging
Determination of relaxation times through MRI relaxometry is most frequently used for
iron quantification (Dusek et al., 2013). Following a radiofrequency pulse, nuclei lose their
transverse magnetization to return to a more ‘relaxed’ state after a short period of time called T2
(Pooley, 2005). In practice, the inherent inhomogeneity of the magnetic field in each voxel
accelerates this loss of transverse magnetization and the real relaxation time is T2* (Huettel, Song,
& McCarthy, 2014; Pooley, 2005). Differences in magnetic susceptibility can increase field
inhomogeneity (Pooley, 2005). With differences in iron concentration between regions, one can
expect greater field inhomogeneities and thus T2* relaxation and its inverse parameter R2* can be
used to measure iron content (Storey et al., 2007).
T2* relaxometry has shown significant increases in nigral iron content due to ageing
(Sohmiya, Tanaka, Aihara, Hirai, & Okamoto, 2001) and PD (Baudrexel et al., 2010; Du et al.,
2019; Martin, Wieler, & Gee, 2008). However, T2* has difficulties due to other local background
sources of inhomogeneity that cause signal loss unrelated to the iron content (Haacke et al., 2005;
Reichenbach et al., 1997). R2* relaxometry has also detected PD-related iron content increases in
vivo (Gelman et al., 1999; Péran et al., 2009; Yao et al., 2009). Post-mortem validation found R2*
relaxometry in grey matter linearly correlates with brain iron determined using chemical methods
(Langkammer et al., 2010). However, R2* maps are affected by intravoxel spin dephasing near
steep phase gradients (e.g. focal iron or air-tissue interfaces; Fernández-Seara & Wehrli, 2000).
Susceptibility weighted imaging (SWI) also relies on spin dephasing from local field
inhomogeneities but independently incorporates phase information along with the magnitude data
(Dusek et al., 2013). In the past, phase images were rarely used because artefacts from the
background field masked the changes in biological tissue (Zhang et al., 2010). Modern SWI
sequences incorporate several features to outperform traditional T2*-weighted GRE sequences:
acquired in 3D mode to reduce time, flow compensated to reduce artefacts, and employed parallel
imaging to reduce time (Dusek et al., 2013; Manova et al., 2009). SN iron was increased in PD
patients as determined by SWI and correlated with motor symptom severity (Zhang et al., 2010).
Much like previous techniques, SWI is influenced by the susceptibility of surrounding tissue in
addition to the local iron content, which can impact iron measurement (Chen et al., 2010;
Hammond et al., 2008). The need for local susceptibility measurement culminated in the
development of quantitative susceptibility mapping (Bilgic et al., 2012; Li & Leigh, 2004).
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1.2.3 Quantitative Susceptibility Mapping
Quantitative susceptibility mapping (QSM) is a novel post-processing technique that
allows calculation of bulk magnetic susceptibility from GRE phase images (Li & Leigh, 2004;
Reichenbach, 2012). QSM requires the following steps: phase unwrapping, background field
removal, and solving the ill-posed phase inverse problem (Robinson et al., 2017). Spatial phase
unwrapping algorithms remove 2𝜋 phase discontinuities from wrapped phase thus making it usable
for QSM (Abdul-Rahman et al., 2007). The background field is then removed to allow for
estimates of susceptibility solely related to the region of interest (ie. brain tissue) and eliminate
superimposed fields to avoid any degrading effect on susceptibility maps (Schweser et al., 2017).
Lastly, the ill-posed inverse problem relating brain tissue phase to the unknown magnetic
susceptibility distribution (dipole inversion) must be solved (Chatnuntawech et al., 2017).
QSM generates relative susceptibility rather than absolute values, which requires
normalization to a reference region (usually cerebrospinal fluid or white matter) to allow betweensubject comparisons (Langkammer et al., 2012). Findings in controls suggest that high correlations
exist between susceptibility measured using QSM and regional iron concentration (Bilgic et al.,
2012; Wu, Du, Xue, Wu, & Zhou, 2012) based on the gold standard histochemical experiment of
Hallgren and Sourander (1958). Furthermore, QSM was validated using a post-mortem tissue
analysis of iron with MRI and Perl’s staining (Langkammer et al., 2012; Sun et al., 2015).
Looking at PD patients, QSM has consistently shown elevations in iron in the whole SN
(Barbosa et al., 2015; Langkammer et al., 2016; Lotfipour et al., 2012; Sethi et al., 2019) and just
the SNc (Du et al., 2016; Guan et al., 2017; Takahashi et al., 2018a,b). QSM also correlated well
with R2* and with iron content in deep gray matter nuclei (Deistung et al., 2013). QSM also
correlated with clinical features of PD including disease duration (Du et al., 2016; He et al., 2015),
motor symptom severity (Langkammer et al., 2016; Wang et al., 2016), and levodopa equivalent
daily dosage (Du et al., 2016; Langkammer et al., 2016). Taken together, this suggests that QSM
has potential to provide a diagnostic biomarker of PD and clinically relevant measure. To date, no
study has measured VTA iron in vivo, but an animal model of PD found VTA iron increases were
not comparable to those observed in the SNc (Hare et al., 2014; Lv, Jiang, Xu, Song, & Xie, 2010).
QSM recently became feasible following computational power improvement, novel
algorithm development, and artefact reduction through improved susceptibility reconstruction
(Schweser et al., 2012; Wharton & Bowtell, 2010). At high fields, contrast-to-noise characteristics
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of GRE phase images exceed magnitude images (Duyn et al., 2007), which means QSM could be
more sensitive to magnetic tissue properties than relaxometry and SWI (Haacke et al., 2005;
Langkammer et al., 2012). There are several differences between susceptibility mapping and
relaxometry (Langkammer et al., 2012). Areas containing diamagnetic and paramagnetic
substances would counteract in bulk susceptibility, but have an additive effect in R2*, which
confounds interpretation of R2* in low iron regions (Langkammer et al., 2012). QSM also reduces
the object orientation dependence of susceptibility in GRE images (Li et al., 2012). While research
suggests that QSM is more sensitive than R2* to estimate brain iron in PD (Barbosa et al., 2015;
Yang, Burciu, & Vaillancourt, 2018), work by Du and colleagues (2018), found QSM measures in
SNc did not change over 18 months, whereas R2* measures did increase in late-stage PD. This
suggests a need to compare both methods for both diagnostic and prognostic purposes in PD. While
relaxometry has been applied in numerous clinical studies, QSM is a recent technique with ongoing
methodological improvements, which may overcome its limitations (Langkammer et al., 2012).

1.3.1 Rationale for Current Study
Although the previous studies detected iron elevation in PD patients relative to controls
using QSM and R2*, the current research aimed to assess whether iron accumulation was specific
in the SNc relative to the entire SN and the VTA. No studies have previously contrasted iron levels
in SNc relative to SNr using objective atlas-based segmentation and instead relied on hand-drawn
segmentation which presents with bias and lacks replicability (Guan et al., 2017; Shin, Lee, Lee,
Rhim, & Park, 2018; Xuan et al., 2017). Further, no previous investigations have assessed iron
accumulation in VTA in vivo in humans due to the structure’s small size, low contrast and lack of
atlases. The recently developed California Institute of Technology 168 (CIT168) probabilistic
subcortical atlas includes the VTA and will be used to outline the structure so that we can assess
its iron levels in early-stages of PD (Alberico et al., 2015; Pauli, Nili, & Tyszka, 2018).
Our understanding of PD pathophysiology leads to the prediction that iron accumulation,
particularly in early stages, will be selectively enhanced in the SNc relative to the SNr and VTA.
This has not been explicitly investigated empirically. Particularly the assessment of VTA in earlystage PD patients is expected to provide a negative control, given that degenerative changes in
VTA are expected in later stages of PD only. If this pattern is borne out, this would suggest that
focusing on SNc iron measures provides a more sensitive diagnostic biomarker of PD and would
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justify the effort of obtaining of sub-regional measurement of iron content rather than simply
assessing whole SN iron levels. Lastly, no studies have compared the differences between field
strengths such as 3 Tesla (T) versus 7T using QSM and R2*. These assessments in the same
patients will allow us to determine any potential advantages of ultra-high field imaging (i.e. 7T)
when measuring iron in midbrain dopaminergic nuclei, and whether this advantage is more
important for QSM or R2* relaxometry (Deistung et al., 2013). The availability of 3T scanners far
exceeds 7T scanners; therefore, biomarkers at 3T are more impactful and relevant in clinic, thus
necessitating separate analyses (Springer et al., 2016).

1.3.2 Objectives
The present study has several objectives which aim to diagnostically tease apart early-stage
PD patients from healthy elderly controls using quantitative MRI of iron. First, it will individually
assess the iron content profiles of the SNc and SNr to determine if researchers should continue to
image the whole SN for QSM and R2* relaxometry. Second, this study will be the first to perform
an in vivo assessment of VTA iron in humans given the importance of this structure in the later
stages of PD. Third, it will compare the diagnostic ability of the two iron-imaging methods: QSM
and R2* relaxometry using receiver operating characteristic (ROC) curve analysis. Lastly, the
study will assess the different field strengths: 3T and 7T to determine if ultra-high field 7T MRI is
necessary for detection of iron overload in early-stage PD.

1.3.3 Predictions
Given the literature on early-stage PD, we predict iron elevation will exist to a greater
degree and perhaps only in the SNc of patients, which will be detected using both imaging
methods. Correspondingly, the SNr and VTA will be spared from iron overload in early stages of
PD and measures that focus on the SNc will provide more sensitive diagnostic biomarkers.
Because it has been suggested that QSM is more sensitive, we expect QSM to outperform R2*
relaxometry in terms of diagnostic ability when assessing the elevated SNc iron as a biomarker.
Lastly, the use of 7T MRI will have a diagnostic advantage over 3T MRI given increased signalto-noise ratio, but we expect that this advantage will be small and perhaps outweighed by the lack
of access to 7T and patients’ and elderly controls’ poorer tolerability of 7T imaging.
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Chapter 2: Methods
2.1 Participants
Seventeen early-stage PD patients and twenty-one elderly healthy controls were recruited
for this study. Each patient was matched with a healthy control within three years of age. Earlystage PD patients were diagnosed within the last five years and had no co-existing diagnosis of
dementia or any other neurological or psychiatric disease, save for mild depression or anxiety.
Disease duration was calculated from the date of physician-confirmed PD diagnosis to the first
imaging session. All PD patients were optimized medically and receiving some form of dopamine
therapy under the management of a movement disorder specialist to be included in the study.
Participants abusing alcohol, prescription or illicit drugs, or taking cognitive-enhancing
medications were excluded, as were patients who were diagnosed before the age of 45, had more
than two first-degree relatives with PD, or had contraindication to MRI. The Health Sciences
Research Ethics Board of the University of Western Ontario approved this study. All participants
provided informed written consent to the approved protocol before beginning the experiment,
according to the Declaration of Helsinki (2013).

2.2 Questionnaires
The Montreal Cognitive Assessment (MoCA) was conducted in all participants to rule out
impaired cognition, such as dementias or mild cognitive impairment (Nasreddine et al., 2005).
MoCA total score was used to rule out global cognitive deficits in early-stage PD patients and
elderly controls and any participants falling into the cognitive impairment test score range was
removed from further analyses.
The Unified Parkinson Disease Rating Scale Part III (UPDRS-III) was conducted on all
participants (Martinez-Martin et al., 1987; Ramaker, Marinus, Stiggelbout, & Van Hilten, 2002).
This neurological assessment was used to measure disease severity, to verify the presence of motor
symptoms in the PD patients’ OFF medication state, and to verify the absence of motor symptoms
in the healthy controls. The UPDRS-III was recorded and later evaluated by a movement disorders
neurologist, PM for interpretation of motor behaviour and symptoms.
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2.3 MRI Data Acquisition
MRI data was collected using a high field 3T Siemens MAGNETOM Prisma whole-body
scanner and an ultra-high field 7T Siemens MAGNETOM scanner at Robarts Research Institute
at the University of Western Ontario. A 32-channel head coil was used in both scanners.
Participants were scanned once on each scanner with up to a maximum of seven days between
sessions using a random counterbalanced design for scanner order.
On the 3T scanner, we first obtained a localizer image for positioning participants. T1weighted (T1w) anatomical scans were obtained for structural information, registration of
quantitative maps and the segmentation of midbrain nuclei using the CIT168 probabilistic
subcortical atlas (Pauli et al., 2018). T1w anatomical images were acquired using a magnetizationprepared rapid gradient echo (MPRAGE) sequence (repetition time (TR) = 2300 ms, echo time
(TE) = 2.98 ms, flip angle = 9°, Field of View (FoV) = 256×256 mm2, 159 slices, voxel size =
1×1×0.9 mm3, receiver bandwidth = 160 Hz/Px, acquisition time = 5:35 min). High resolution
GRE images (Deistung et al., 2008) were acquired with an rf-spoiled, flow compensated 3D
gradient echo sequence with six echoes (TE ranging from 8.09 ms to 40.49 ms and an equal interval
of 6.48 ms), and (TR = 52 ms, flip angle = 20°, FoV = 224×224 mm2, 96 slices, voxel size =
0.5×0.5×2 mm3, receiver bandwidth = 160 Hz/Px, acquisition time = 8:30 min).
On the 7T scanner, we obtained a localizer image for positioning participants. T1w images
were acquired with a magnetization-prepared 2 rapid gradient echo (MP2RAGE) sequence (TR =
6000 ms, TE = 2.73 ms, flip angle1 = 4°, flip angle2 = 5°, FoV = 240×240 mm2, 224 slices, voxel
size = 0.7×0.7×0.7 mm3, receiver bandwidth = 150 Hz/Px, acquisition time = 10:14 min). High
resolution GRE images were acquired with an rf-spoiled, flow compensated 3D gradient echo
sequence with four echoes (TE ranging from 4.61 ms to 15.50 ms and an equal interval of 3.63
ms), and (TR = 35 ms, flip angle = 13°, FoV = 220×220 mm2, 128 slices, voxel size = 0.8×0.8×0.8
mm3, receiver bandwidth = 310 Hz/Px, acquisition time = 9:07 min).

2.4 MRI Data Postprocessing
T1w Postprocessing – T1w image processing was performed using FMRIB Software Library
(FSL) 5.0.11 (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/) and Advanced Normalization Tools (ANTs)
2.2 (http://picsl.upenn.edu/software/ants). Brain Extraction based on nonlocal Segmentation
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Technique (BEaST) was used for skull-stripping T1w images from both field strengths (Eskildsen
et al., 2013) using code from: <https://github.com/khanlab/beast>. Then bias fields for skullstripped 3T and 7T T1w images were corrected using N4BiasFieldCorrection, followed by
intensity normalization.
Gradient Echo Magnitude Postprocessing – GRE magnitude images from all echoes were
averaged then skull-stripped using BEaST. Skull-stripped averaged GRE magnitude images were
then linearly registered to the final postprocessed T1w images using FMRIB's Linear Image
Registration Tool (FLIRT).
R2* Relaxometry Image Generation – Non-linear least squares estimation of R2* was calculated
at each voxel using the Levenberg–Marquardt algorithm (http://netlib.org/minpack/; Levenberg,
1944; Marquardt, 1963) on the complex signal. All code for R2* image generation is available at
(https://github.com/AlanKuurstra/qsm_sstv).
Quantitative Susceptibility Map Generation – An in-house singular value decomposition algorithm
based on Walsh, Gmitro, and Marcellin (2000) was employed to reconstruct the GRE raw data,
described in (https://cds.ismrm.org/protected/13MProceedings/files/3739.PDF). This algorithm
gives the least squares best estimate of the magnetization and avoids phase singularities. QSM
processing was performed as follows: spatial phase unwrapping was accomplished using a 3D best
path algorithm (Abdul-Rahman et al., 2007). The frequency at each voxel was then estimated by
weighted least squares; each phase echo was weighted by the local signal-to-noise ratio in the
corresponding T2* image. Finally, background removal and dipole inversion were performed
simultaneously using a single-step QSM algorithm (Chatnuntawech et al., 2017). Since
susceptibility values calculated by dipole inversion are relative with unknown offset, an offset was
set by forcing the average value within the brain to be zero parts per billion (ppb). All code for
QSM image generation is available at (https://github.com/AlanKuurstra/qsm_sstv).
Quantitative Map Postprocessing – The transformation matrices from the average GRE magnitude
to T1w image registrations were used to perform linear registration of both QSM and R2* images
onto T1w images using FLIRT. QSM images were then offset using the average susceptibility in
16

the cerebrospinal fluid of each participant as a reference, which allows for between subject
comparisons to be performed given that the susceptibility values are relativistic and not absolute
(Langkammer et al., 2012).
Atlas-Based Segmentation – The CIT168 probabilistic subcortical atlas developed by Pauli and
colleagues (2018) available at (https://neurovault.org/collections/3145/) was used for single atlasbased segmentation. This high-resolution atlas clearly demarcates the SNc, SNr, and VTA based
on data from young controls in the Human Connectome Project database. The limitations of this
atlas are its use of only 3T data being non-ideal for use in our 7T data and the young population,
which may not account for age-related anatomical changes in our sample. Nevertheless, this is one
of the better available atlases for subcortical segmentation.
Atlas-based segmentation of each participant was performed using the NiftyReg linear and
deformable b-spline registration tools to the CIT168 atlas in MNI152 space (Non-linear 2009c
1mm) as shown in Figure 2 (Modat et al., 2014). Volumes of the midbrain nuclei: SNc, SNr, and
VTA were extracted from these segmentations. Quality assurance for each registration was
performed.
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Figure 2. Segmentation of midbrain nuclei on QSM and R2* maps of a healthy control. Top row
shows SNc, SNr, and VTA from CIT168 atlas mapped onto T1w images in axial and coronal planes. Middle
row shows a 3D model of the midbrain nuclei in axial plane, superior view (left) and coronal plane, posterior
view (right). Bottom row shows midbrain nuclei on QS map (left) and R2* map (right) of the same healthy
control in axial planes. SNc is shown in blue, SNr in yellow and VTA in red for all images.
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2.5 Statistical Analysis
Demographic data for all participants was compared between groups using a one-way
analysis of variance (ANOVA) looking at age and MoCA total scores, along with a chi-square test
for sex. For the three midbrain nuclei, early-stage PD patients were compared to healthy controls
for the average susceptibility in ppb in QSM images and average R2* values (1/s) in R2* images.
All measures were considered separately in each hemisphere given the asymmetrical presentation
of symptoms in early-stage PD.
To assess the effects of early-stage PD on the QSM and R2* relaxometry measures of the
SNc, a 2 × 2 × 2 repeated measures analysis of covariance (RM-ANCOVA) was conducted with
Group (PD versus Control) as the between-subjects factor and Hemisphere (Left versus Right) and
Scanner (3T versus 7T) as within-subjects variables controlling for age and sex as covariates.
Subcortical iron deposits increase with age and males display higher iron levels than females, even
when accounting for age, thus warranting both as covariates for our analyses (Persson et al., 2015).
Separate 2 × 2 RM-ANCOVAs were performed at each of the two field strengths (3T and 7T) to
assess for biomarker potential at each field strength individually. The 2 × 2 RM-ANCOVAs were
conducted for QSM and R2* measures of the SNc at both field strengths using Group as the
between-subjects factor and Hemisphere as the within-subjects variable controlling for age and
sex as covariates. For all statistical analyses, p < 0.05 was used as the statistical threshold.
Benjamini-Hochberg correction (1995) was used to control the false discovery rate at q = .05 and
to avoid stringent approaches such as Bonferroni family wise error correction. All RM-ANCOVAs
were then repeated using the QSM and R2* averages of the SNr and the VTA with identical factors,
variables, and covariates as those previously described.
ROC curves were constructed for any measures showing significant group differences
between early-stage PD patients and healthy controls to assess for their potential to discriminate
between groups at a participant level. To optimally test for discriminatory ability, average
susceptibility and R2* values were sorted based on the more affected or less affected hemisphere
as defined by the UPDRS-III motor assessment rather than using left and right hemispheres. This
allows us to account for the asymmetric presentation associated with early-stage PD. The more
affected hemisphere (MAH) was defined as being contralateral to the more affected body side and
the less affected hemisphere (LAH) was contralateral to the less affected body side based on the
UPDRS-III. The area under the ROC curve (AUC) was calculated to compare the diagnostic
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accuracy between measures. The highest Youden index was also used to determine the best
diagnostic cut-off value based on sensitivity and specificity for each of the measures.
The AUCs of the MAH and LAH were compared within the same method to test for
significant differences in diagnostic accuracy using the method established by Hanley and McNiel
(1983). The AUC of the MAH was compared between the different iron imaging methods to test
if any method significantly outperformed others based on diagnostic accuracy of early-stage PD
patients compared to healthy controls.
To assess the nuclei volumes being sampled at each field strength, the 7T T1w image whole
brain volume was registered to the 3T T1w image whole brain volume of each participant using
FLIRT. The translation matrix of this registration was then applied to the respective segmented
volumes of the SNc, SNr, and VTA to register the 3T volumes onto the 7T volumes using FLIRT.
The percentage of overlap between the “3T onto 7T” volumes and the original 7T volumes was
computed using Dice similarity coefficient for the SNc, SNr, and VTA (Dice, 1945). To assess if
similar volumes were sampled between scanners, Dice similarity coefficients were then compared
using a 3 × 2 repeated measures analysis of variance (RM-ANOVA) using Group (PD versus
Control) as between-subjects factor and Nucleus (SNc, SNr, and VTA) as within-subjects variable.
All statistical analyses were performed using IBM SPSS Statistics (version 23, IBM Corp.,
Armonk, NY, USA). The Hanley-McNeil method for AUC comparison was performed using
MedCalc (version 18, MedCalc Software).
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Chapter 3: Results
3.1.1 Demographics
For general demographics, early-stage PD patients did not differ significantly in age
(F(1,36) = 1.480, MSe = 71.8, padj = .23) or sex (χ2(1) = 1.799, padj =.18) from the healthy controls
(Table 1). No significant differences were found on the MoCA total scores between groups
(F(1,36) = 2.014, MSe = 14.5, padj = .17), indicating similar general cognitive ability and a lack of
global cognitive impairment in these groups. The early-stage PD patients had an average disease
duration of 2.50 ± 1.80 years with six patients having had PD for 0-1 years, six for 2-3 years and
five for 4-5years indicating an even spread of patients across our selected disease duration range.
Table 1. Demographics and clinical information for early-stage PD patients and controls. Cells
show ratio of female to male for sex, age in years, PD duration in years, ratio for more affected hemisphere in
PD patients and MoCA total scores. Averages reported as means ± standard error mean (NS = not significant).

Control

PD

p-value

12 F : 9 M
65.0 ± 1.5

6 F : 11 M
67.8 ± 1.7

NS
NS

PD Duration

-

2.5 ± 0.4

-

MAH

-

14 L : 3 R

-

28.1 ± 0.5

27.1 ± 0.7

NS

Sex
Age

MoCA Total

3.2.1 QSM in the SNc
A 2 × 2 × 2 RM-ANCOVA of SNc average susceptibility from QSM data was performed
using Group as the between-subjects factor with Hemisphere and Scanner as the within-subjects
variables controlling for age and sex as covariates. A significant main effect of Group was found
[F(1,31) = 16.137, MSe = 2930, padj = .002], which suggests early-stage PD patients had higher
iron deposition regardless of scanner field strength (Figure 3). There was no significant main effect
of Hemisphere [F(1,31) = 3.090, MSe = 607, padj = .26] or Scanner [F(1,31) < 1]. No significant
interactions were found for Hemisphere*Group [F(1,31) = 2.123, MSe = 607, padj = .31],
Scanner*Group [F(1,31) < 1], Hemisphere*Scanner [F(1,31) = 2.891, MSe = 581, padj = .26], or
Hemisphere*Scanner*Group [F(1,31) < 1].
Separate 2 × 2 RM-ANCOVAs were performed at the two field strengths (3T and 7T) to
assess for biomarker potential at each field strength individually. Again, using Group as the
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between-subjects factor with Hemisphere as the within-subjects variable controlling for age and
sex as covariates. For 3T data, a significant main effect of Group was found [F(1,34) = 13.051,
MSe = 2475, padj = .01] with PD patients showing higher average susceptibility than controls,
suggesting increased iron deposition (Figure 3A). No significant main effect of Hemisphere was
found [F(1,34) = 6.476, MSe = 666, padj = .08], suggesting similar iron deposition in both
hemispheres overall (Figure 3A). Lastly, no significant Hemisphere*Group interaction was found
[F(1,34) = 1.973, MSe = 666, padj = .29].
For 7T data, a significant main effect of Group was found [F(1,31) = 11.134, MSe = 1830,
padj = .01] with PD patients showing higher susceptibility and iron deposition again (Figure 3B).
Looking at Hemisphere, no significant main effect of Hemisphere was found [F(1,31) < 1] with
no significant Hemisphere*Group interaction [F(1,31) < 1]. Taken together, these results suggest
that QSM at both 3T and 7T detected bilateral elevated iron content in the SNc of early-stage PD
patients when compared to age-matched healthy controls.
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A

SNc

3T

**

B

SNc

7T

**

Figure 3. Average susceptibility for the SNc of early-stage PD patients and healthy controls at 3T
and 7T. Data show paired hemispheric averages for all participants in scatterplots with corresponding
boxplots demonstrating median and interquartile range in black lines. SNc average susceptibility in ppb
from QSM at both field strengths are shown as dashed white lines. Significant group differences were found
at both field strengths with PD showing increased iron deposition. nCT = 21, nPD = 17. * p ≤ .05, ** p ≤ .01
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3.2.2 R2* in the SNc
A 2 × 2 × 2 RM-ANCOVA of SNc average R2* value from R2* relaxometry was
performed using Group as the between-subjects factor with Hemisphere and Scanner as the withinsubjects variables controlling for age and sex as covariates. There was a significant main effect of
Scanner [F(1,31) = 11.289, MSe = 80.5, padj = .01] suggesting 7T R2* values were higher than 3T
showing field strength dependence (Figure 4). No significant main effect of Group was found
[F(1,31) = 5.901, MSe = 159, padj = .08], which suggests early-stage PD patients had similar iron
deposition to elderly controls regardless of scanner field strength (Figure 4). No significant main
effect of Hemisphere was found [F(1,31) < 1]. In addition, no significant interactions were found
for Hemisphere*Group [F(1,31) = 1.035, MSe = 23.2, padj = .52], Scanner*Group [F(1,31) = 2.127,
MSe = 80.5, padj = .29], Hemisphere*Scanner [F(1,31) < 1], or Hemisphere*Scanner*Group
[F(1,31) = 2.608, MSe = 40.4, padj = .27].
Separate 2 × 2 RM-ANCOVAs were again performed at both field strengths using Group
as the between-subjects factor with Hemisphere as the within-subjects variable controlling for age
and sex as covariates. For 3T data, no significant main effect of Group was found [F(1,34) = 2.265,
MSe = 90.0, padj = .29] with PD patients showing similar R2* values as controls, suggesting similar
iron deposition (Figure 4A). No significant main effect of Hemisphere was found [F(1,34) < 1],
suggesting no difference in iron deposition between hemispheres (Figure 4A). No significant
Hemisphere*Group interaction was found [F(1,34) = 5.262, MSe = 22.4, padj = .09].
For 7T data, a marginally significant main effect of Group was found [F(1,31) = 7.465,
MSe = 148, padj = .052] with PD patients showing higher iron deposition (Figure 4B). No
significant main effect of Hemisphere was found [F(1,31) < 1] with no significant
Hemisphere*Group interaction [F(1,31) < 1]. Taken together, these results suggest that R2* only
detected elevated iron content in the SNc of early-stage PD patients at 7T and not at 3T.
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Figure 4. Average R2* values for the SNc of early-stage PD patients and healthy controls at 3T
and 7T. Data show paired hemispheric averages for all participants in scatterplots with corresponding
boxplots demonstrating median and interquartile range in black lines. SNc average R2* values in 1/s from
R2* at both field strengths are shown as dashed white lines. Marginally significant differences were found
between groups at 7T with PD showing increased iron deposition. nCT = 21, nPD = 17. ¤ padj = .052
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3.2.3 ROC Curve Analyses in the SNc
For diagnostic biomarker assessments, the MAH and LAH were used instead of the right
and left hemisphere conventions to better account for early-stage PD asymmetry. The MAH based
on the more symptomatic body side from the UPDRS-III is of greater clinical relevance; therefore,
results from only this hemisphere are reported here.
Looking at QSM 3T data, the ROC curves for SNc average susceptibility show the MAH
is a significant predictor for distinguishing PD patients (AUC = .871, p < .001; Figure 5). Based
on the highest Youden index, the optimal cut-off value for distinguishing PD patients in the MAH
is 137.5 ppb (Sensitivity = 0.824, Specificity = 0.905). Similarly, ROC curves for the SNc average
susceptibility at 7T show that the MAH is a significant predictor (AUC = .807, p = .002) with an
optimal cut-off value of 137.9 ppb (Sensitivity = 0.667, Specificity = 0.95; Figure 5). Both field
strengths had almost identical optimal cut-off values.
For R2* data at 3T, ROC curves show that the average R2* values of the MAH SNc was
not a significant predictor (AUC = .565, p = .503) with an optimal cut-off value of 36.3 s-1
(Sensitivity = .647, Specificity = .550; Figure 6). Looking at the SNc average R2* values at 7T,
however, the MAH was a significant predictor (AUC = .725, p = .022) with an optimal cut-off
value of 65.2 s-1 (Sensitivity = .750, Specificity = .750; Figure 6).
Using the Hanley-McNeil method (1983), we compared the AUC of the measures with
significant diagnostic accuracy which were QSM at 3T, QSM at 7T and R2* at 7T. This method
allows comparison of AUCs which are based on the same sample of participants. Comparing the
MAH SNc to LAH SNc, QSM at 3T had a significant difference between hemispheres (Z = 2.307,
p = .02; Figure 5), whereas QSM at 7T (Z = 0.924, p = .36; Figure 5) and R2* at 7T (Z = 1.023,
p = .31) did not (Figure 6). This suggests that QSM at 3T was somewhat sensitive to the asymmetry
of early-stage PD, given that the MAH outperformed the LAH in terms of diagnostic accuracy.
Comparing the MAH SNc between the three different methods, QSM 3T versus R2* 7T
was marginally significant (Z = 1.514, p = .065) suggesting QSM 3T out-performed R2* 7T based
on diagnostic accuracy. No significant differences were found between QSM 3T versus QSM 7T
(Z = 0.643, p = .52) and QSM 7T versus R2* 7T (Z = 0.707, p = .48). Taken together, this suggests
that QSM outperforms R2* relaxometry in terms of diagnostic accuracy using iron in the SNc of
early-stage PD patients compared to controls.
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MAH AUC = .807
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Figure 5. ROC curves for MAH and LAH of SNc average susceptibility at 3T and 7T. Data show
more affected (black) and less affected (red) hemispheres from QSM at 3T and 7T with the optimal cut-off point
(white circle) based on the highest Youden index. MAH AUC and optimal cut-off sensitivity and specificity are shown.
nCT = 21, nPD = 17

MAH
MAH
LAH
LAH

MAH
LAH

R2* 7T SNc
MAH AUC = .725
Sensitivity = .750
Specificity = .750

R2* 3T SNc
MAH AUC = .565
Sensitivity = .647
Specificity = .550

Figure 6. ROC curves for MAH and LAH of SNc average R2* value at 3T and 7T. Data show more
affected (black) and less affected (red) hemispheres of from R2* relaxometry at 3T and 7T with the optimal cut-off
point (white circle) based on the highest Youden index. MAH AUC and optimal cut-off sensitivity and specificity are
shown. nCT = 21, nPD = 17
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3.3.1 QSM in the SNr
A 2 × 2 × 2 RM-ANCOVA of SNr average susceptibility from QSM was performed using
Group as the between-subjects factor with Hemisphere and Scanner as the within-subjects
variables controlling for age and sex as covariates. No significant main effect of Group was found
[F(1,31) < 1], which suggests early-stage PD patients had similar iron deposition to elderly
controls regardless of scanner field strength (Figure 7). There was no significant main effect of
Scanner [F(1,31) < 1] suggesting similar values between field strengths (Figure 7). No significant
main effect of Hemisphere was found [F(1,31) < 1]. Lastly, no significant interactions were found
for Hemisphere*Group [F(1,31) = 1.000, MSe = 572, padj = .85], Scanner*Group [F(1,31) < 1],
Hemisphere*Scanner [F(1,31) < 1], or Hemisphere*Scanner*Group [F(1,31) < 1].
Separate 2 × 2 RM-ANCOVAs were performed at 3T and 7T using Group as the betweensubjects factor with Hemisphere as the within-subjects variable controlling for age and sex as
covariates. For 3T data, no significant main effect of Group was found [F(1,34) < 1] with PD
patients showing similar average susceptibility as elderly controls, suggesting similar iron
deposition (Figure 7A). No significant main effect of Hemisphere was found [F(1,34) < 1],
suggesting no difference in iron deposition between hemispheres (Figure 7A) and no significant
Hemisphere*Group interaction was found [F(1,34) < 1].
For 7T data, no significant main effect of Group was found [F(1,31) < 1] with PD patients
showing similar average susceptibility and iron deposition (Figure 7B). No significant main effect
of Hemisphere was found [F(1,31) < 1] along with no significant Hemisphere*Group interaction
[F(1,31) < 1]. Taken together, these observations suggest no differences in SNr iron content were
found between early-stage PD patients and controls using QSM at 3T and 7T. Given that the main
effect of Group was not significant for SNr iron content imaged using QSM, the ROC curve
analyses were not performed on our SNr measures.
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Figure 7. Average susceptibility for the SNr of early-stage PD patients and healthy controls at 3T
and 7T. Data show paired hemispheric averages for all participants in scatterplots with corresponding
boxplots demonstrating median and interquartile range in black lines. SNr average susceptibility values in
ppb from QSM at both field strengths are shown as dashed white lines. No significant differences were
found between groups at both field strengths. nCT = 21, nPD = 17
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3.3.2 R2* in the SNr
A 2 × 2 × 2 RM-ANCOVA of SNr average R2* values was performed using Group as the
between-subjects factor with Hemisphere and Scanner as within-subjects variables controlling for
age and sex as covariates. There was a significant main effect of Scanner [F(1,31) = 12.875,
MSe = 78.2, padj = .01] suggesting higher R2* values at 7T overall (Figure 8). No significant main
effect of Group was found [F(1,31) = 1.020, MSe = 281, padj = .77], which suggests early-stage
PD patients have similar iron to controls regardless of scanner field strength (Figure 8). No
significant main effect of Hemisphere was found [F(1,31) < 1]. Lastly, no significant interactions
were found for Hemisphere*Group [F(1,31) = 1.079, MSe = 54.8, padj = .77], Scanner*Group
[F(1,31) = 2.457, MSe = 89.3, padj = .41], Hemisphere*Scanner [F(1,31) < 1], or
Hemisphere*Scanner*Group [F(1,31) < 1].
Separate 2 × 2 RM-ANCOVAs were performed at 3T and 7T using Group as the betweensubjects factor with Hemisphere as the within-subjects variable controlling for age and sex as
covariates. For 3T data, no significant main effect of Group was found [F(1,34) < 1] with PD
patients showing similar average R2* values as elderly controls, suggesting similar iron deposition
(Figure 8A). No significant main effect of Hemisphere was found [F(1,34) < 1], suggesting no
difference in iron deposition between hemispheres (Figure 8A) and no significant
Hemisphere*Group interaction was found [F(1,34) = 1.170, MSe = 24.1, padj = .77].
For 7T data, no significant main effect of Group was found [F(1,31) = 2.066, MSe = 244,
padj = .46] with PD patients showing similar average susceptibility and iron deposition (Figure 8B).
No significant main effect of Hemisphere was found [F(1,31) < 1] along with no significant
Hemisphere*Group interaction [F(1,31) < 1]. Taken together, these observations suggest no
differences in SNr iron content were found between early-stage PD patients and controls using
R2* at 3T and 7T. Given that the main effect of Group was not significant for SNr iron content
imaged using R2* relaxometry, the ROC curve analyses were not performed on our SNr measures.
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Figure 8. Average R2* values for the SNr of early-stage PD patients and healthy controls at 3T
and 7T. Data show paired hemispheric averages for all participants in scatterplots with corresponding
boxplots demonstrating median and interquartile range in black lines. SNr average R2* values in 1/s from
R2* at both field strengths are shown as dashed white lines. No significant differences were found between
groups at both field strengths with PD showing similar averages to controls. nCT = 21, nPD = 17
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3.4.1 QSM in the VTA
A 2 × 2 × 2 RM-ANCOVA of VTA average susceptibility was performed using Group as
the between-subjects factor with Hemisphere and Scanner as within-subjects variables controlling
for age and sex as covariates. No significant main effect of Group was found [F(1,31) = 2.530,
MSe = 2040, padj = .37], which suggests PD patients had similar VTA iron deposition to controls
regardless of scanner (Figure 9). There was no significant main effect of Scanner [F(1,31) = 2.262,
MSe = 1925, padj = .40] suggesting similar values between field strengths (Figure 9). No significant
main effect of Hemisphere was found [F(1,31) < 1]. Lastly, no significant interactions were found
for Hemisphere*Group [F(1,31) < 1], Scanner*Group [F(1,31) < 1], Hemisphere*Scanner
[F(1,31) = 3.514, MSe = 159, padj = .34], or Hemisphere*Scanner*Group [F(1,31) < 1].
Separate 2 × 2 RM-ANCOVAs were performed at 3T and 7T using Group as the betweensubjects factor and Hemisphere as the within-subjects variable controlling for age and sex. For 3T,
no significant main effect of Group was found [F(1,34) = 2.457, MSe = 1972, padj = .37] with PD
patients showing similar average susceptibility as elderly controls, suggesting similar iron
deposition (Figure 9A). No significant main effect of Hemisphere was found [F(1,34) = 3.437,
MSe = 438, padj = .34], suggesting no difference in iron deposition between hemispheres with no
significant Hemisphere*Group interaction [F(1,34) < 1; Figure 9A].
For 7T data, no significant main effect of Group was found [F(1,31) < 1] with PD patients
showing similar average susceptibility and iron deposition (Figure 9B). No significant main effect
of Hemisphere was found [F(1,31) = 2.675, MSe = 149, padj = .36] along with no significant
Hemisphere*Group interaction [F(1,31) < 1]. Taken together, these observations suggest no
elevation in VTA iron was found in early-stage PD patients using QSM at 3T and 7T. Given that
the main effect of Group was not significant for VTA iron content imaged using QSM, the ROC
curve analyses were not performed on our VTA measures.
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Figure 9. Average susceptibility for the VTA of early-stage PD patients and healthy controls at
3T and 7T. Data show paired hemispheric averages for all participants in scatterplots with corresponding
boxplots demonstrating median and interquartile range in black lines. VTA average susceptibility values in
ppb from QSM at both field strengths are shown as dashed white lines. No significant differences were
found between groups at both field strengths. nCT = 21, nPD = 17
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3.4.2 R2* in the VTA
A 2 × 2 × 2 RM-ANCOVA of VTA average R2* value was performed using Group as the
between-subjects factor with Hemisphere and Scanner as within-subjects variables controlling for
age and sex as covariates. There was a significant main effect of Scanner [F(1,31) = 9.635,
MSe = 9.31, padj = .02] suggesting higher R2* values at 7T versus 3T (Figure 10). No significant
main effect of Group was found [F(1,31) < 1], which suggests PD patients had similar VTA iron
deposition to controls regardless of scanner (Figure 10). No significant main effect of Hemisphere
was found [F(1,31) < 1], suggesting similar iron levels between hemispheres. Lastly, no significant
interactions were found for Hemisphere*Group [F(1,31) < 1], Scanner*Group [F(1,31) = 2.679,
MSe = 59.6, padj = .36], Hemisphere*Scanner [F(1,31) < 1], or Hemisphere*Scanner*Group
[F(1,31) = 4.511, MSe = 15.8, padj = .27].
Separate 2 × 2 RM-ANCOVAs were performed at 3T and 7T using Group as the betweensubjects factor and Hemisphere as the within-subjects variable controlling for age and sex. For 3T,
no significant main effect of Group was found [F(1,34) = 1.465, MSe = 71.7, padj = .56] with PD
patients showing similar average R2* values as elderly controls, suggesting similar iron deposition
(Figure 10A). No significant main effect of Hemisphere was found [F(1,34) = 1.279, MSe = 16.7,
padj = .58], suggesting no difference in iron deposition between hemispheres with no significant
Hemisphere*Group interaction [F(1,34) = 5.581, MSe = 16.7, padj = .27; Figure 10A].
For 7T data, no significant main effect of Group was found [F(1,31) < 1] with PD patients
showing similar average R2* values and iron deposition (Figure 10B). No significant main effect
of Hemisphere was found [F(1,31) < 1] along with no significant Hemisphere*Group interaction
[F(1,31) = 1.422, MSe = 19.2, padj = .57]. Taken together, these observations suggest no elevation
in VTA iron was found in early-stage PD patients using R2* relaxometry at 3T and 7T. Given that
the main effect of Group was not significant for VTA iron content using R2* relaxometry, the
ROC curve analyses were not performed on our VTA measures.
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Figure 10. Average R2* values for the VTA of early-stage PD patients and healthy controls at 3T
and 7T. Data show paired hemispheric averages for all participants in scatterplots with corresponding
boxplots demonstrating median and interquartile range in black lines. VTA average R2* values in 1/s from
R2* at both field strengths are shown as white dashed lines. No significant differences were found between
groups at both field strengths with PD showing similar iron deposition to controls. nCT = 21, nPD = 17
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3.5.1 Dice Similarity Coefficients between Scanners
To assess if similar volumes were being sampled between scanners, Dice similarity
coefficients were calculated for the midbrain nuclei in each participant (Figure 11). Despite their
small volumes, there was good overlap (Range of average Dice similarity coefficients: 0.67 - 0.82).
A 3 × 2 RM-ANOVA using Group as between-subjects factor and Nucleus (SNc, SNr, and VTA)
as within-subjects variable was performed. Mauchly's test of sphericity for Dice similarity
coefficients indicated that the assumption of sphericity was violated (χ2(2) = 10.984, p = .004).
Following Greenhouse-Geisser correction, a significant main effect of Nucleus was found
[F(1.56,53.0) = 302, MSe = .254, padj < .001] suggesting differences in between-scanner overlap
across the midbrain nuclei (Figure 11). No significant main effect of Group [F(1,34) < 1] or
Nucleus*Group interaction [F(1.56,53.0) = 1.458, MSe = .001, padj = .24] was found suggesting
similar between-scanner overlap between PDs and controls across midbrain nuclei (Figure 11).
Midbrain

Dice Similarity Coefficient

CT
PD

SNc

SNr

VTA

Figure 11. Dice similarity coefficients between scanners for midbrain structures of PD patients
and controls. Data shows the overlap of bilateral ROIs between scanners after linear registration of 3T ROIs
onto 7T ROIs. No significant differences were found between groups. nCT = 21, nPD = 17
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Chapter 4: Discussion
4.1 General Summary of Results
In the present study, iron in the dopaminergic midbrain nuclei was successfully quantified
in early-stage PD patients and healthy, age-matched elderly controls using QSM and R2*
relaxometry at 3T and 7T MRI. Using the recently developed CIT168 probabilistic subcortical
atlas, we bilaterally segmented the SNc, SNr, and VTA to measure average susceptibility and R2*
values in these nuclei as proxies for iron concentration (Pauli et al., 2018). Additionally, the first
in vivo assessment of human VTA iron was performed.
As predicted, SNc iron was significantly elevated bilaterally in early-stage PD patients
based on average susceptibility from QSM at 3T and 7T. Using R2*, SNc iron elevation was not
detected at 3T, but showed marginal significance at 7T, which suggests lower potential for clinical
translation given the lack of sensitivity at the common 3T field strength. For diagnostic biomarker
assessment of SNc iron, ROC curve analyses found QSM in the MAH of the SNc had diagnostic
accuracy in the good to excellent range with AUCs from 0.81-0.87 at both field strengths.
Conversely, R2* at 3T failed to reach significance for diagnostic accuracy while R2* at 7T was
significant with an AUC of 0.73, which is still below the “good biomarker” cut-off of AUC = 0.80.
These observations support the notion that QSM is more sensitive and accurate diagnostically than
R2* relaxometry regarding SNc iron elevation in PD (Langkammer et al., 2016).
No significant group differences were detected in the SNr and VTA for either iron imaging
technique at both field strengths. This suggests similar SNr and VTA iron content in early-stage
PD patients and controls, as well as sparing of these structures from iron overload in early-stage
PD as predicted. These observations highlight the need to separate the two SN subregions and
measure SNc iron content in isolation to enhance sensitivity and diagnostic accuracy. The VTA
succeeded as a negative control since iron elevation would be expected in late stage PD.
Looking between field strengths, no apparent advantage of 7T was found over 3T for QSM
in the SNc. QSM was independent of field strength while R2* demonstrated dependence and
proportionality with field strength as expected (Langkammer et al., 2016). Lastly, Dice similarity
coefficients showed no differences in between-scanner overlap between groups. There was good
overlap despite Dice score bias for small structures such as the SNc and VTA (Pauli et al., 2018).
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Taken together, these findings suggest that QSM is a better diagnostic imaging tool for detecting
the increased SNc iron content observed in PD when compared to R2* relaxometry.

4.2 Assessment of Iron Imaging as a Diagnostic Biomarker of PD
Iron content in the SNc successfully differentiated early-stage PD patients from agematched controls. Given that iron elevation was noted only in the SNc in early-stage PD, it is
beneficial to split the SN into its two constituents to improve sensitivity and diagnostic accuracy
(Barbosa et al., 2015; Martin et al., 2008; Sofic, Paulus, Jellinger, Riederer, & Youdim, 1991).
Our QSM and R2* averages in the SNc and SNr agree with previous findings (Barbosa et al., 2015;
Du et al., 2016; Guan et al., 2017; Sethi et al., 2019). Furthermore, the relationship of higher iron
in SNr compared to SNc is upheld in our findings, though only SNc iron could differentiate PD
patients from controls (Good, Olanow & Perl, 1992; Kwon et al., 2012; Sofic et al., 1991). Our
findings support previous work which suggests that whole SN iron measures are not sensitive to
early-stage PD and control differences (Barbosa et al., 2015; He et al., 2015). This suggests that
proper demarcation of the SNc/SNr border is imperative to isolate SNc and derive the most
sensitive and accurate biomarker of early-stage PD. To date, segmentation algorithms have had
difficulty delineating the subtle difference between the SNc and SNr, let alone providing
boundaries of the much smaller VTA (Eapen et al., 2011; Pauli et al., 2018). In fact, the CIT168
subcortical atlas is the first to include the SNc, SNr, and importantly the VTA (Pauli et al., 2018).
To our knowledge, this study is the first to report in vivo measurements of iron in the VTA
using MRI. The VTA had the lowest average values on both imaging techniques, which suggests
that this nucleus has lower overall iron content than the SN regions (Hare et al., 2014; Hare &
Double, 2016). This observation fits in line with histology that reports higher iron in the SNc and
SNr relative to other dopaminergic midbrain nuclei (Dexter et al., 1991; Hare et al., 2014). The
finding of statistically equivalent VTA iron between early-stage PD and controls was entirely
predicted given that VTA degeneration occurs in later stages (Alberico et al., 2015). We tested
only early-stage PD patients, with less than five years disease duration and who did not have
cognitive impairment. VTA degeneration at later stages of PD is presumed to cause non-motor
symptoms, particularly cognitive impairment (Alberico et al., 2015). The absence of VTA
differences between our PD and control groups provided an important negative control.
Furthermore, these differences in overall iron content could potentially explain the differences in
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vulnerability between both nuclei in PD, given that the VTA is affected at later stages. However,
this is made with caution as further analyses must rule out other differences between these nuclei
that could contribute to differences in vulnerability to neurodegeneration (Hare et al., 2014).
Previous work comparing the two iron imaging techniques of QSM and R2* has led to
similar results as those reported here. Using the Hanley-McNeil method (1983), we found that
QSM had superior diagnostic sensitivity and accuracy, making it the preferred in vivo iron
quantification technique (Barbosa et al., 2015; Du et al., 2016; Langkammer et al., 2016;
Murakami et al., 2015). For example, Deistung and colleagues (2013) found only QSM provided
qualitative discrimination of the SNc and SNr boundary when compared to magnitude and R2*
images. This superior boundary demarcation could potentially have contributed to QSM’s greater
ability to detect iron overload in the SNc of PD patients compared to healthy controls in our study.
QSM has also shown potential to detect unique iron “fingerprints” for differential diagnosis of
parkinsonian syndromes (Ito et al., 2017). Furthermore, the effects of phase differences with nonlocal tissue is not accounted for in R2* relaxometry, which introduces noise from surrounding
structures (e.g., from the SNr to the SNc and vice versa), which reduces sensitivity (Dusek et al.,
2013; Sethi et al., 2019). The lower sensitivity of R2* relaxometry to detect SNc iron elevation in
PD has been previously reported (Barbosa et al., 2015; Du et al., 2016; Guan et al., 2015;
Langkammer et al., 2013; Sethi et al., 2019). QSM also shows stronger correlation with clinical
severity scores in patients with PD than R2* relaxometry (Du et al., 2016; Langkammer et al.,
2016). The advantages of using susceptibility for iron quantification, instead of using phase
directly, is that susceptibility is not dependent on imaging parameters such as main field strength,
object orientation, and echo time (Haacke et al., 2015; Liu, Li, Tong, Yeom, & Kuzminski, 2014,
Liu et al., 2017). Furthermore, susceptibility has shown a linear relationship with iron content
using ferritin phantoms and post-mortem analyses (Langkammer et al., 2010; Zheng et al., 2013).
A recent paper suggests that 1 ppb in susceptibility is equivalent to a value close to 1 μg of iron
per g of wet tissue (Ghasaban et al., 2018; Liu et al., 2016). Although R2* has been heavily utilized
to quantify iron content, QSM is clearly a more promising method in terms of sensitivity and
specificity (Barbosa et al., 2015; Du et al., 2016; Haacke et al., 2015; Langkammer et al., 2016).
This study found no apparent diagnostic advantage of 7T MRI over 3T MRI when using
the average susceptibility or R2* value features of the three midbrain nuclei in direct comparisons.
Any between-field strength comparison, however, is made with caution given the different voxel
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sizes and shapes of the sequences between scanners. The smaller axial in-plane voxel size of the
GRE scan at 3T could provide better discriminatory ability of boundaries than the larger isometric
voxel size at 7T (Springer et al., 2016). Furthermore, different image features such as variance and
entropy were not analyzed, which may prove a clear advantage for 7T MRI over 3T MRI. Lastly,
there were differences in overlap based on the Dice coefficients, which tend to be biased for
smaller structures, which can further limit between scanner comparisons (Pauli et al., 2018). The
purpose of the between-field strength comparisons was strictly to determine if the diagnostic
capability of QSM and R2* was sufficiently sensitive at lower field strengths (i.e. 3T). QSM in
the SNc held up at 3T, although the between-group difference in SNc iron assessed with R2* was
only marginally significant at 7T (Sethi et al., 2019). This observation is important for clinical
translation as 3T scanners are more widely available than 7T scanners. Consequently, imaging
biomarkers that are sensitive and accurate at 3T hold much more clinical potential than those
discovered at 7T (Springer et al., 2016).
Looking at the ROC curves, the diagnostic accuracy of our iron imaging methods falls in
line with previous reports (Barbosa et al., 2015; Du et al., 2016; Li et al., 2019). QSM falls in the
good to excellent range of diagnostic accuracy with an AUC from 81 – 87%. R2* relaxometry was
not significant at 3T and reached a diagnostic accuracy of 73% at 7T. Du and colleagues (2016)
reported a diagnostic accuracy of 83% for QSM and 78% for R2* relaxometry when looking at
the hand-drawn SNc at 3T MRI. Their R2* results have slightly higher diagnostic accuracy at 3T
than ours, but this can be explained by the longer disease duration in their PD patients
compensating for the lower sensitivity of R2*. The disease duration in their study was 5.5 years
whereas it was only 2.5 years in ours.
A study by Li and colleagues (2019) at 3T, found only QSM and not R2* could
significantly distinguish between PD patients and controls when looking at average values in the
SN. They found that second-order features like entropy of QSM and R2* images had better results
with diagnostic accuracies of 88-89% and 73-77%, respectively. The discriminatory ability of their
SN second-order values falls in line with our SNc first-order values, which further highlights the
improved sensitivity achieved when looking at the SNc in isolation rather than the whole SN in
PD. Their work also suggests that features other than the mean value of the image could prove
useful in future for detecting ideal diagnostic features, or perhaps generating a more sensitive
combinatorial measure (Li et al., 2019). It is therefore evident that iron imaging, especially QSM,
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demonstrates great potential as a diagnostic biomarker of PD. Though this novel structural imaging
technique is still being developed and perfected, it demonstrates an ability to distinguish PD
patients from healthy controls with strong diagnostic accuracy.

4.3 Comparison of Iron Imaging with Other Imaging Biomarkers
Although this study focused on iron imaging, other measures have been explored in trying
to identify PD biomarkers. As mentioned earlier, neuromelanin is a pigment which has
neuroprotective effects through iron chelation. Neuromelanin is lost as a result of PD and patients
have about 50% of the neuromelanin of an age-matched control, which has been visualized using
in vivo imaging (Sasaki et al., 2006). Recently, neuromelanin-sensitive T1w MRI has been
developed that can discriminate neuromelanin loss in the SN of PD patients compared to controls.
Further, neuromelanin MRI is sensitive to PD progression (Fabbri et al., 2017; Yang et al., 2018).
The ‘swallow-tail’ sign describes the normal axial imaging appearance of the nigrosome1 within the SN using high resolution MRI (Schwarz et al., 2014). The loss of the ‘swallow-tail’
sign in PD has a reported diagnostic accuracy above 90% using susceptibility imaging (Schwarz
et al., 2014). This change can be detected with QSM using the elevated iron content and
neuromelanin-sensitive MRI using the decreased neuromelanin, which suggests a point of
comparison and conversion between these two diagnostic techniques (Li et al., 2019). Takahashi
and colleagues (2018a,b) reported on two occasions that neuromelanin imaging outperformed
QSM (NM AUC = 0.86 versus QSM AUC = 0.68), but their methods used neuromelanin images
to segment regions-of-interest and had lower quality segmentations and GRE sequences than those
reported here. Nevertheless, both techniques have potential for combinatorial analyses to better
understand structural changes in the SNc using T1w and T2w sequences.
Diffusion-weighted imaging (DWI) has shown some promise as a PD biomarker (Khan et
al., 2019). Given that nigrostriatal pathway degeneration is a cardinal feature of early PD, followed
by mesolimbic and mesocortical pathway abnormality, DWI measurement can provide insight into
changes in these pathways for diagnosis and staging (Khan et al., 2019; Tuite, 2016). Good
diagnostic accuracy using reduced fractional anisotropy in the SN of PD patients has been reported
using DWI (Deng, Wang, Yang, Li, & Yu., 2018; He et al., 2018; Huddleston et al., 2017).
However, there is noticeable variation in results among DWI studies, so an understanding of the
full potential of DWI in PD is not yet established (Schwarz et al., 2013). Nonetheless, DWI can
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differentially diagnose PD from other Parkinsonian syndromes like multiple system atrophy
(Chung et al., 2009) and progressive supranuclear palsy (Seppi et al., 2003). In white matter, iron
imaging underperforms diagnostically in PD patients because myelin content confounds the signal
of the iron content (Langkammer et al., 2012; Guan et al., 2018). In this way, DWI might
complement iron imaging to provide a measure of white matter degeneration whereas QSM can
index gray-matter abnormalities in early-stage PD (Yang et al., 2018). Clearly, MRI biomarkers
are multi-faceted in the analysis of PD features, with each technique showing benefits and costs
relative to the others (Tuite, 2016). Despite all these investigations, MRI structural biomarkers of
PD are only beginning to be developed with novel approaches and analysis techniques.

4.4 Limitations
The CIT168 probabilistic subcortical atlas used in this study has several limitations. The
atlas is derived using a younger cohort, is based only on 3T MRI data, and uses averaging of
numerous brains to raise the contrast-to-noise ratio between regions for delineation (Pauli et al.,
2018). The atlas cohort is roughly 35 years younger than that of our sample, which means structural
changes related to ageing are likely unaccounted for in these midbrain structures. However, since
both PD patients and controls are age-matched and we have used the same atlas in both groups,
this moderates any disadvantages based on using an atlas derived in healthy young controls. The
atlas was derived in 3T MRI, which likely has reduced resolution compared to 7T MRI and altered
boundary delineation; ideally a 7T version should be employed in our 7T data. Lastly, averaging
results in the loss of some small-scale individual features such as the SNc/SNr boundary, which
despite registration accuracy results in boundaries that can no longer be mapped back to the
individual exactly (Pauli et al., 2018). This inherent limitation of atlases impacts the delineation
of these midbrain nuclei, which can only be practically solved by having repeated scans of the
same person, a costly solution (Pauli et al., 2018).
Other limitations include the implementation of cerebrospinal fluid (CSF) as a reference
structure in QSM (Deistung et al., 2013). This structure was chosen based on its frequent
appearance in the QSM literature (Acosta-Cabronero et al., 2018). Studies have reported that the
inter-subject variability of susceptibility is higher in CSF relative to frontal white matter or cortical
grey matter and propose that one of the latter be used instead (Betts, Acosta-Cabronero, CardenasBlanco, Nestor, & Duzel, 2016; Feng, Deistung, & Reichenbach, 2018). We ran an exploratory
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analysis of cortical grey matter and found no major differences in the relationships compared to
CSF. The CSF is a more generalizable reference structure given that tissue types are differentially
affected by neurological diseases (Acosta-Cabronero et al., 2018). This would suggest that the CSF
reference structure is sufficient for our analyses, but frontal white matter could be implemented as
a second reference structure in future studies (Ropele & Langkammer, 2017).
Given the novelty of QSM, more work needs to be done regarding the ideal method for
generating the susceptibility maps (Yu et al., 2019). Although we showed one technique, others
may be more or less successful in a diagnostic capacity, thus warranting consortia to compare the
various techniques (Acosta-Cabronero et al., 2018). Our technique could be further improved upon
through prospective motion correction for QSM at 7T and using identical isometric voxel sizes to
allow for between field strength comparison (Karsa, Punwani, & Shmueli, 2019; Mattern et al.,
2019). Lastly, there are some white matter fibres and calcium deposits in these deep grey matter
nuclei which could be reducing our sensitivity and estimation of iron values (Buch et al., 2015;
Deistung, Schwerser, & Reichenbach, 2017; Lancione et al., 2017). Looking at iron in white matter
presents with difficulties using QSM due to the influence of myelin content on susceptibility,
which reduces the ability of QSM to detect nigrostriatal degeneration (Langkammer et al., 2012).

4.5 Future Directions
The single atlas employed in this study could be improved upon through multi-atlas
segmentation or segmentation algorithm approaches to better define nuclei boundaries. To our
knowledge, no other atlases include all three midbrain nuclei hence our single atlas approach. With
the development of better subcortical atlases, a multi-atlas approach could be conducted to better
determine accurate structural boundaries. Furthermore, the development of novel segmentation
algorithms that can accurately segment these small subcortical structures could bypass the need
for atlases. Work by Eapen and colleagues (2011) found some success with SN segmentation at
7T, however, the VTA was more difficult to define and required manual tracing using the SNc and
red nucleus as boundaries for the structure. Some segmentation algorithms have been developed
to segment the striatum directly in QSM images, but more work is needed before they can
accurately define the SNc/SNr boundary and delineate the elusive VTA nucleus. Being able to
segment directly on QSM and R2* images would remove the step of registration to T1w images,
reducing any alignment concerns.
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Another avenue worth pursuing is the parcellation of the SNc as previous work has shown
an important distinction between dorsal and ventral tiers of SNc in PD (Gibb & Lees, 1991; Haber,
Fudge, & MacFarland, 2000). Though it is not possible to clearly distinguish these tiers in vivo
using individual structural MRI, combining QSM and DWI could be employed to overcome this
limitation (Pauli et al., 2018). Acosta-Carbenero and colleagues (2015) have shown iron elevation
in the SNc and ventral lateral SN using whole brain QSM. A region-of-interest analysis of the
ventral lateral SNc is warranted given this area is first affected by PD (Gibb & Lees, 1991). Our
lab intends to parcellate the SNc using probabilistic tractography from DWI to better localize SNc
iron accumulation and develop an understanding of the potential functional impacts based on
reciprocal connections with the striatum and cortex (Khan et al., 2019).
Given that QSM has been shown here to detect early-stage PD, further experimentation is
needed in even earlier stages of PD. We aim to look at de novo PD patients, immediately upon
diagnosis, as well as in pre-clinical populations such as in patients with Rapid eye movement
(REM) sleep behaviour disorder (RBD) to verify QSM’s potential as an early diagnostic or preclinical biomarker, respectively (Postuma, 2017). Imaging de novo patients could provide insight
about structural changes in the brain at the time of PD diagnosis. This could be used in combination
with or in place of neurological assessment depending upon biomarker accuracy (Kim et al., 2018;
Vaillancourt et al., 2009). Patients with RBD have become a major focus in neurodegeneration
research as they present a unique opportunity to study changes that precede the onset of motor
symptoms of alpha-synucleinopathies, such as PD. A majority of RBD patients will convert to PD
or another alpha-synucleinopathy, such as multiple system atrophy (MSA) and Lewy body
dementia (LBD) within ten years of their RBD diagnosis making it the strongest predictor of
neurodegeneration (Postuma et al., 2009; Postuma et al., 2015). If changes in SNc iron content can
be found in patients with RBD who later convert to PD, such a biomarker would allow trials of
medications at earlier stages when these interventions have a better chance of efficacy.
Neuropathology investigations have reported the spatial patterns of dopaminergic neuron
loss and iron accumulation within the SNc occur in parallel during PD (Massey et al., 2017).
Following advancements and improvements to segmentation and QSM methodology, we can
expect more accurate estimates of the true iron content in PD patients and increased sensitivity to
subregions within the SNc, suggesting promise for iron imaging in clinical settings.
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4.6 Conclusions
The present study found excessive iron accumulation in the SNc of early-stage PD patients
with sparing of the SNr and VTA. This fits with our understanding of the pathophysiology of PD.
This SNc iron overload was detected using QSM and R2* relaxometry. QSM in the SNc had higher
diagnostic accuracy and outperformed R2* as a diagnostic biomarker of PD at both 3T and 7T.
R2* of SNc did not distinguish PD patients from controls at 3T though QSM showed this
difference strongly. Using QSM, there was no detectable advantage of using 7T relative to 3T. In
this way, QSM demonstrated superior potential for clinical translation given its efficacy at 3T
MRI. Capitalizing on our understanding of iron accumulation in the specific brain regions in earlystage PD and across disease progression, iron imaging could provide valuable biomarkers of PD,
enabling accurate and reproducible diagnosis and prognosis of the disease. Finally, establishing
sensitive and specific biomarkers of PD is a necessary step toward developing the first diseasemodifying therapies in this neurodegenerative disorder, first described over 200 years ago.
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Appendices
Appendix A: Participant Inclusion/Exclusion Criteria
Healthy Controls

Early-stage PD Patients

No contraindications for MRI scanning

No contraindications for MRI scanning

No diagnosis of a movement disorder

Diagnosis of idiopathic PD from a licensed
neurologist specializing in movement disorders

No history of:
No history of (unrelated to PD):
1. Neurological illness
1. Neurological illness
2. Psychiatric illness
2. Psychiatric illness
3. Neuro-trauma
3. Neuro-trauma
4. Psychosis or hallucinations
4. Psychosis or hallucinations
5. Substance abuse (eg. alcohol, drugs)
5. Substance abuse (eg. alcohol, drugs)
Normal or corrected-to-normal vision
Normal or corrected-to-normal vision
No previous participation in the study

No previous participation in the study

Not currently taking cognitive-enhancing
medications including:
1. Donepezil
2. Galantamine
3. Rivastigimine
4. Memantine
5. Methylphenidate

Not currently taking cognitive-enhancing
medications including:
1. Donepezil
2. Galantamine
3. Rivastigimine
4. Memantine
5. Methylphenidate

No clinical diagnosis of dementia or mild
cognitive impairment

No clinical diagnosis of dementia or mild
cognitive impairment
Currently prescribed and taking dopaminergic
medication
PD duration < 5 years from date of diagnosis
No suspicion of familial form of PD (greater than
2 first degree relatives with PD diagnosis)
Stable and non-rapidly progressing parkinsonism
No history of deep brain stimulation treatment or
neurological surgery
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Appendix B: Consent Form
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Appendix C: Health & Demographics Questionnaire
Please print and fill out this form as accurately as possible and bring it with you to your first appointment
session. If you are attending your appointment with another participant, please ensure you both have
your own personal copies filled out.
1. Basic Demographic Information
Date of Birth: _________________

Age: _______

Weight: _____________

Height: ___________

Sex: _________

Handedness: _____________

First language: __________________

Other languages: ___________________________

Level of Education and total years (e.g. 4 years high school, 4 years university, etc.)
_______________________________________________________________________
Occupation: ______________________________
2. Health-Related Information
A. Smoking History (please circle): Never Smoker

Ex-Smoker

Current Smoker

If current smoker, indicate how many years and how many cig/day: _______________________
If ex-smoker, indicate year that you quit; how many years smoking; how many cig/day:
______________________________________________________________________________
B. Alcohol History
Average number of drinks per week: _____________
Has there ever been heavy alcohol consumption? (please circle)

Yes

No

If yes, when, for how long, and estimate your weekly alcohol consumption during that time:
______________________________________________________________________________
C. Other Drug History
Have you ever taken street drugs or other drugs that were not prescribed by a physician? (please circle)
Yes

No

If yes, when, what drugs, how frequently and over what period of time?
______________________________________________________________________________
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D. Eye Glasses (only if applicable)
What is the prescription of your eye glasses? ______________
Without the aid of glasses are you able to see near objects well? (please circle) Yes

No

Without the aid of glasses are you able to see far objects well? (please circle)

No

Yes

E. Parkinson’s Disease (only if applicable)
What year were you diagnosed with Parkinson’s disease? _________________
Which side of the body is more affected? _________________
3. Previous Medical Problems
Have you had any major health problems, or do you have any chronic, ongoing medical conditions such
as high blood pressure, high cholesterol, diabetes, thyroid problems, multiple sclerosis or epilepsy? Have
you had any strokes, heart attacks/ heart surgeries, significant head trauma, or cancer? If you've had
cancer, what kind and what treatments did you receive (e.g. chemotherapy)? Have you ever had more
than one seizure? Answer in the space below.

4. Family Medical Problems
Is there anyone in your family with a neurological or serious psychiatric illness such as PD, Huntington's,
epilepsy, strokes at a young age (< 50 for men and < 60 for women)? Is there anyone who had trouble
walking or with balance, needing a wheelchair or a walker at a young age? Any family members with
dementia (such as Alzheimer's), schizophrenia, bipolar/manic depression, or severe depression or anxiety
requiring hospitalization or close follow up by a psychiatrist? Answer in the space below.

5. Current Medication
Please list any medications you are currently taking, what they are treating for specifically, and the
prescribed dosage.
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Appendix D: Montreal Cognitive Assessment
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Appendix E: Montreal Cognitive Assessment Evaluation Scale
MoCA Version August 18, 2010 © Z. Nasreddine MD www.mocatest.org

Montreal Cognitive Assessment (MoCA) Administration and Scoring Instructions
The Montreal Cognitive Assessment (MoCA) was designed as a rapid screening instrument for mild
cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive
functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and
orientation. Time to administer the MoCA is approximately 10 minutes. The total possible score is 30
points; a score of 26 or above is considered normal.
1. Alternating Trail Making:
Administration: The examiner instructs the subject: "Please draw a line, going from a number to a letter
in ascending order. Begin here [point to (1)] and draw a line from 1 then to A then to 2 and so on. End
here [point to (E)]."
Scoring: Allocate one point if the subject successfully draws the following pattern:
1 −A- 2- B- 3- C- 4- D- 5- E, without drawing any lines that cross. Any error that is not immediately selfcorrected earns a score of 0.
2. Visuoconstructional Skills (Cube):
Administration: The examiner gives the following instructions, pointing to the cube: “Copy this drawing
as accurately as you can, in the space below”.
Scoring: One point is allocated for a correctly executed drawing.
• Drawing must be three-dimensional
• All lines are drawn
• No line is added
• Lines are relatively parallel and their length is similar (rectangular prisms are accepted) A point is not
assigned if any of the above-criteria are not met.
3. Visuoconstructional Skills (Clock):
Administration: Indicate the right third of the space and give the following instructions: “Draw a clock.
Put in all the numbers and set the time to 10 past 11”.
Scoring: One point is allocated for each of the following three criteria:
• Contour (1 pt.): the clock face must be a circle with only minor distortion acceptable (e.g., slight
imperfection on closing the circle);
• Numbers (1 pt.): all clock numbers must be present with no additional numbers; numbers must be in the
correct order and placed in the approximate quadrants on the clock face; Roman numerals are acceptable;
numbers can be placed outside the circle contour;
• Hands (1 pt.): there must be two hands jointly indicating the correct time; the hour hand must be clearly
shorter than the minute hand; hands must be centred within the clock face with their junction close to the
clock centre.
A point is not assigned for a given element if any of the above-criteria are not met.
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4. Naming:
Administration: Beginning on the left, point to each figure and say: “Tell me the name of this animal”.
Scoring: One point each is given for the following responses: (1) lion (2) rhinoceros or rhino (3) camel or
dromedary.
5. Memory:
Administration: The examiner reads a list of 5 words at a rate of one per second, giving the following
instructions: “This is a memory test. I am going to read a list of words that you will have to

remember now and later on. Listen carefully. When I am through, tell me as many words as you
can remember. It doesn’t matter in what order you say them”.
Mark a check in the allocated space for each word the subject produces on this first trial. When the
subject indicates that (s)he has finished (has recalled all words), or can recall no more
words, read the list a second time with the following instructions: “I am going to read the same list for a
second time.Try to remember and tell me as many words as you can, including words you said the first
time.”
Put a check in the allocated space for each word the subject recalls after the second trial.
At the end of the second trial, inform the subject that (s)he will be asked to recall these words again by
saying, “I will ask you to recall those words again at the end of the test.”
Scoring: No points are given for Trials One and Two.
6. Attention: Forward Digit Span:
Administration: Give the following instruction: “I am going to say some numbers and when I am through,
repeat them to me exactly as I said them”. Read the five number sequence at a rate of one digit per
second.
Backward Digit Span:
Administration: Give the following instruction: “Now I am going to say some more numbers, but when I
am through you must repeat them to me in the backwards order.” Read the three number sequence at a
rate of one digit per second.
Scoring: Allocate one point for each sequence correctly repeated, (N.B.: the correct response for the
backwards trial is 2-4-7).
Vigilance:
Administration: The examiner reads the list of letters at a rate of one per second, after giving the
following instruction: “I am going to read a sequence of letters. Every time I
say the letter A, tap your hand once. If I say a different letter, do not tap your hand”.
Scoring: Give one point if there is zero to one errors (an error is a tap on a wrong letter or a failure to tap
on letter A).
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Serial 7s:
Administration: The examiner gives the following instruction: “Now, I will ask you to count by
subtracting seven from 100, and then, keep subtracting seven from your answer until I tell you to stop.”
Give this instruction twice if necessary.
Scoring: This item is scored out of 3 points. Give no (0) points for no correct subtractions, 1 point for one
correction subtraction, 2 points for two-to-three correct subtractions, and 3 points if the participant
successfully makes four or five correct subtractions. Count each correct subtraction of 7 beginning at 100.
Each subtraction is evaluated independently; that is, if the participant responds with an incorrect number
but continues to correctly subtract 7 from it, give a point for each correct subtraction. For example, a
participant may respond “92 – 85 – 78 – 71 – 64” where the “92” is incorrect, but all subsequent numbers
are subtracted correctly. This is one error and the item would be given a score of 3.
7. Sentence Repetition:
Administration: The examiner gives the following instructions: “I am going to read you a sentence.
Repeat it after me, exactly as I say it [pause]: I only know that John is the one to help today.”
Following the response, say: “Now I am going to read you another sentence.Repeat it after me, exactly as
I say it [pause]: The cat always hid under the couch when dogs were in the room.”
Scoring: Allocate 1 point for each sentence correctly repeated. Repetition must be exact. Be alert for
errors that are omissions (e.g., omitting "only", "always") and substitutions/additions
(e.g., "John is the one who helped today;" substituting "hides" for "hid", altering plurals, etc.).
8. Verbal fluency:
Administration: The examiner gives the following instruction: “Tell me as many words as you can think
of that begin with a certain letter of the alphabet that I will tell you in a moment. You can say any kind of
word you want, except for proper nouns (like Bob or Boston), numbers, or words that begin with the same
sound but have a different suffix, for example, love, lover, loving. I will tell you to stop after one minute.
Are you ready? [Pause] Now, tell me as many words as you can think of that begin with the letter F. [time
for 60 sec]. Stop.”
Scoring: Allocate one point if the subject generates 11 words or more in 60 sec. Record the subject’s
response in the bottom or side margins.
9. Abstraction:
Administration: The examiner asks the subject to explain what each pair of words has in common,
starting with the example: “Tell me how an orange and a banana are alike”. If the subject answers in a
concrete manner, then say only one additional time: “Tell me another way in which those items are
alike”. If the subject does not give the appropriate response (fruit), say, “Yes, and they are also both
fruit.” Do not give any additional instructions or clarification. After the practice trial, say: “Now, tell me
how a train and a bicycle are alike”. Following the response, administer the second trial, saying: “Now
tell me how a ruler and a watch are alike”.
Do not give any additional instructions or prompts.
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Scoring: Only the last two item pairs are scored. Give 1 point to each item pair correctly answered. The
following responses are acceptable:
Train-bicycle = means of transportation, means of travelling, you take trips in both;
Ruler-watch = measuring instruments, used to measure.
The following responses are not acceptable: Train-bicycle = they have wheels; Ruler-watch = they have
numbers.
10. Delayed recall:
Administration: The examiner gives the following instruction: “I read some words to you earlier, which I
asked you to remember. Tell me as many of those words as you can remember.” Make a check mark for
each of the words correctly recalled spontaneously without any cues, in the allocated space.
Scoring: Allocate 1 point for each word recalled freely without any cues.
Optional: Following the delayed free recall trial, prompt the subject with the semantic category cue
provided below for any word not recalled. Make a check mark ( √ ) in the allocated space if the subject
remembered the word with the help of a category or multiple-choice cue. Prompt all non- recalled words
in this manner. If the subject does not recall the word after the category cue, give him/her a multiplechoice trial, using the following example instruction,
“Which of the following words do you think it was, NOSE, FACE, or HAND?”
Use the following category and/or multiple-choice cues for each word, when appropriate:
FACE: category cue: part of the body multiple choice: nose, face, hand
VELVET: category cue: type of fabric multiple choice: denim, cotton, velvet
CHURCH: category cue: type of building multiple choice: church, school, hospital
DAISY: category cue: type of flower multiple choice: rose, daisy, tulip
RED: category cue: a colour multiple choice: red, blue, green
Scoring: No points are allocated for words recalled with a cue. A cue is used for clinical information
purposes only and can give the test interpreter additional information about the type of memory disorder.
For memory deficits due to retrieval failures, performance can be improved with a cue. For memory
deficits due to encoding failures, performance does not improve with a cue.
11. Orientation:
Administration: The examiner gives the following instructions: “Tell me the date today”. If the subject
does not give a complete answer, then prompt accordingly by saying: “Tell me the
[year, month, exact date, and day of the week].” Then say: “Now, tell me the name of this place, and
which city it is in.”
Scoring: Give one point for each item correctly answered. The subject must tell the exact date and the
exact place (name of hospital, clinic, office). No points are allocated if subject makes an error of one day
for the day and date.
TOTAL SCORE: Sum all sub-scores listed on the right-hand side. Add one point for an individual who
has 12 years or fewer of formal education, for a possible maximum of 30 points. A final total score of 26
and above is considered normal.
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Appendix F: UPDRS-III Protocol
UPDRS Protocol
Ask at the start “which arm/hand do you have most difficulty with?”
Always start with LESS impaired side
Only model for a few seconds, then stop
“This is subject (PD/CTRL #), session #, (on/off) medication.”
1. Film face at rest for a few seconds
2. Ask patient to speak one-two sentences (for dysarthria)
•

“Today is a very nice day outside”

•

“I am at the University for an experiment”

3. Evaluate resting tremor
1. hands relaxed on thighs
2. with cognitive stressing “Close your eyes and name the months of the year
backward from December”
4. Evaluate tone
a. Bilateral upper extremities
5. Evaluate postural tremor
a. Hands outstretched
b. Fingertips apposed (forming wings with arms ensuring fingers are not touching)
6. Evaluate action tremor
a.

Finger-to-nose (finger target should be arms-length away and in same position)

7. Evaluate bradykinesia
a. Finger taps (pinching) “Big and fast”
b. Hand opening-closing movements “Big and fast”
c. Pronation-supination movements “Fast as you can”
d. Toe-tapping (minimum 3 inches off ground)
8. Ask patient to rise from the chair without the assistance of his/her arms (arms crossed
over chest) “Fold your arms across and chest and stand up”
9. Evaluate gait, ask to walk up and down hallway 2-3 times, with turns
10. Pull test “Try to maintain your balance and limit yourself to one step backwards”
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Appendix G: Covariate Analysis for Age and Sex
QSM: 2 × 2 × 2 RM-ANCOVA p-values for Age and Sex covariate main effects and interactions
of the SNc, SNr, and VTA. Significant values after Benjamini-Hochberg correction are shown in bold font.
.
Main Effect
Age
Sex
SNc
.923
.453
SNr
.002 *
< .001 *
VTA
.948
.663
.
Interaction
Hemisphere*Age Hemisphere*Sex
SNc
.086
.672
SNr
.830
.717
VTA
.150
.794
.
Interaction
Scanner*Age
Scanner*Sex
SNc
.405
.388
SNr
.599
.149
VTA
.338
.362
.
Interaction
Hemisphere*Scanner*Age Hemisphere*Scanner*Sex
SNc
.072
.838
SNr
.268
.874
VTA
.001 *
.071
QSM 3T: 2 × 2 RM-ANCOVA p-values for Age and Sex covariate main effects and interactions
of the SNc, SNr, and VTA. Significant values after Benjamini-Hochberg correction are shown in bold font.
.
Main Effect
Age
Sex
SNc
.427
.477
SNr
.059
.062
VTA
.202
.678
.
Interaction
Hemisphere*Age Hemisphere*Sex
SNc
.011
.780
SNr
.555
.577
VTA
.073
.316
QSM 7T: 2 × 2 RM-ANCOVA p-values for Age and Sex covariate main effects and interactions
of the SNc, SNr, and VTA. Significant values after Benjamini-Hochberg correction are shown in bold font.
.
Main Effect
Age
Sex
SNc
.551
.885
SNr
.007
< .001 *
VTA
.459
.873
.
Interaction
Hemisphere*Age Hemisphere*Sex
SNc
.970
.617
SNr
.334
.859
VTA
.124
.978
89

R2*: 2 × 2 × 2 RM-ANCOVA p-values for Age and Sex covariate main effects and interactions
of the SNc, SNr, and VTA. Significant values after Benjamini-Hochberg correction are shown in bold font.
.
Main Effect
Age
Sex
SNc
.153
.626
SNr
.238
.564
VTA
.838
.625
.
Interaction
Hemisphere*Age Hemisphere*Sex
SNc
.799
.122
SNr
.641
.286
VTA
.740
.095
.
Interaction
Scanner*Age
Scanner*Sex
SNc
.090
.074
SNr
.245
.848
VTA
.744
.382
.
Interaction
Hemisphere*Scanner*Age Hemisphere*Scanner*Sex
SNc
.528
.340
SNr
.791
.817
VTA
.991
.011
R2* 3T: 2 × 2 RM-ANCOVA p-values for Age and Sex covariate main effects and interactions
of the SNc, SNr, and VTA. Significant values after Benjamini-Hochberg correction are shown in bold font.
.
Main Effect
Age
Sex
SNc
.994
.292
SNr
.081
.674
VTA
.667
.620
.
Interaction
Hemisphere*Age Hemisphere*Sex
SNc
.815
.851
SNr
.608
.288
VTA
.333
.875
R2* 7T: 2 × 2 RM-ANCOVA p-values for Age and Sex covariate main effects and interactions
of the SNc, SNr, and VTA. Significant values after Benjamini-Hochberg correction are shown in bold font.
.
Main Effect
Age
Sex
SNc
.038
.251
SNr
.687
.721
VTA
.712
.347
.
Interaction
Hemisphere*Age Hemisphere*Sex
SNc
.542
.119
SNr
.675
.456
VTA
.813
.006
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Appendix H: ROC Curve Analyses of Left and Right Hemisphere of the SNc

QSM 7T SNc
L AUC = .777, p = .006
R AUC = .720, p = .028

QSM 3T SNc
L AUC = .849, p < .001
R AUC = .725, p = .018

Figure S1. ROC Curves for Left and Right Hemisphere of the SNc for QSM at 3T and 7T. Left
(black) and right (red) hemisphere shown with AUCs and respective p values reported. nCT = 21, nPD = 17.

R2* 3T SNc
L AUC = .565, p = .503
R AUC = .697, p = .061

R2* 7T SNc
L AUC = .722, p = .024
R AUC = .656, p = .111

Figure S2. ROC Curves for Left and Right Hemisphere of the SNc for R2* at 3T and 7T. Left
(black) and right (red) hemisphere shown with AUCs and respective p values reported. nCT = 21, nPD = 17.

Left hemisphere appears to have higher AUC values than right hemisphere likely due to
our sample having more PD patients who were right body side affected suggesting the left
hemisphere would be more affected. QSM still boasts larger AUCs than R2* relaxometry.
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